Stockwinners Market Radar for June 05, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EDT Zura Bio director buys $500K in common stock - In a regulatory filing, Zura Bio disclosed that its director Amit Munshi bought 117.6K shares of common stock on June 5th in a total transaction size of $500K.

20:15 EDT Cathie Wood's ARK Investment bought 124K shares of Cerus today

20:13 EDT Cathie Wood's ARK Investment bought 228K shares of Ginkgo Bioworks today

19:02 EDT HNR Acquisition affirms intent to purchase equity interest of Pogo Resources - HNR Acquisition Corp. affirmed its intent to purchase all equity interests in Pogo Resources, LLC and its subsidiary, LH Operating, LLC. HNRA has previously announced its agreement to purchase all the equity interests in Pogo under a Membership Interest Purchase Agreement. Pogo's oil and gas holdings include an approximate 13,700-acre producing leasehold located in the prolific Permian Basin in Eddy County, New Mexico.

18:15 EDT Cenovus Energy updates production impact of Alberta wildfires - Cenovus Energy has safely restarted approximately 62,000 barrels of oil equivalent per day of production, from the 85,000 BOE/d impacted in May due to wildfires. Assuming the current wildfire conditions continue, Rainbow Lake operations are expected to return to production within seven to 10 days, which represents approximately 20,000 BOE/d. About 3,000 BOE/d remains offline awaiting power infrastructure to be rebuilt in various remote locations. As staff have been able to access sites, to date no significant damage has been identified. The overall wildfire situation continues to be closely monitored and other assets, including the company's oil sands operations and Lloydminster complex, have not been impacted.

17:41 EDT Planet Fitness CEO buys $649.9K in common stock - In a regulatory filing, Planet Fitness disclosed that its CEO Chris Rondeau bought 10K shares of common stock on June 5th in a total transaction size of $649.9K.

17:35 EDT Take-Two's Strauss Zelnick sells $1.3M in shares - The Chairman of Two Interactive Software Strauss Zelnick disclosed in a regulatory filing that he had sold 9,537 shares of company stock at $137.67 per share on June 1, for a total transaction amount of $1,312,989.

17:24 EDT Metals Acquisition shareholders approve proposed business combination - Metals Acquisition Corp announced that MAC's shareholders voted to approve, among other things: (i) its proposed business combination to acquire from Glencore Operations Australia Pty Limited 100% of the issued share capital of Cobar Management Pty. Limited, which owns and operates the Cornish, Scottish and Australian mine; and (ii) its proposed merger with Metals Acquisition Limited to occur immediately prior to the Business Combination. The vast majority of the votes cast at the meeting voted to approve the Business Combination and the Merger. MAC Limited will be continuing as the surviving company following the Merger. The Business Combination is scheduled to close on June 15, 2023. As a result of the Business Combination, CMPL will become a wholly-owned indirect subsidiary of New MAC. The common stock and warrants of New MAC are set to begin trading on the New York Stock Exchange on June 16, 2023 under the ticker symbols, "MTAL" and "MTAL.WS", respectively.

17:16 EDT Old Dominion reports certain less-than-truckload operating metrics for May - Old Dominion Freight Line reported certain less-than-truckload operating metrics for May 2023. Revenue per day decreased 15.7% as compared to May 2022 primarily due to a 14.4% decrease in LTL tons per day. The change in LTL tons per day was attributable to an 11.4% decrease in LTL shipments per day and a 3.4% decrease in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight, excluding fuel surcharges, increased 0.1% and 7.9%, respectively, as compared to the same period last year. Greg Gantt, President and CEO of Old Dominion, commented, "Old Dominion's revenue results for May reflect continued softness in the domestic economy as well as a decrease in fuel surcharge revenue. While our volumes decreased on a year-over-year basis, our LTL shipments per day remained relatively consistent with the first quarter of 2023 and our yield continued to improve. Our quarter-to-date LTL revenue per hundredweight, excluding fuel surcharges, increased 7.9% due primarily to the ongoing execution of our yield-management strategy. We remain focused on delivering superior service at a fair price to support our consistent, cost-based approach to managing yields, despite the year-over-year decrease in volumes. As we continue to deliver our unmatched value proposition, and consistently execute on the other key elements of our long-term strategic plan, we believe we will win market share and increase shareholder value over the long term."

17:02 EDT Sangoma Technologies announces planned share sale by Star2Star Holdings - Sangoma Technologies "announced that Star2Star Holdings, LLC has filed a notice of intention to distribute securities in connection with a proposed sale of up to 665,812 common shares of the Company, representing up to approximately 2% of the issued and outstanding common shares. The common shares are expected to be sold through the facilities of the Toronto Stock Exchange or private transactions. Holdings is controlled by Norman Worthington, the Company's Interim Executive Chairman, and its largest shareholder. As previously announced, the proposed sales are being undertaken to generate the cash needed by Holdings to pay its tax obligations that were triggered by the recent distribution of the remaining share consideration payable to the former stockholders of StarBlue Inc. in connection with the Company's 2021 acquisition of StarBlue."

16:51 EDT Politan says 'meaningful change is clearly needed' on Masimo board - Politan Capital Management, a 9% shareholder of Masimo Corporation, commented on the Company's recent announcement that it would authorize expanding its Board and adding Politan nominee Michelle Brennan - contingent on the reelection of all incumbent Masimo directors at the upcoming Annual Meeting of Stockholders. Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, stated: "Meaningful change is clearly needed on Masimo's Board. For years, Masimo has gone to extreme and well-documented lengths to avoid this occurring. Making Michelle's appointment contingent on all incumbent directors being elected is not progress - it is yet another defensive maneuver to impede shareholder-driven change. Michelle would be an exceptional addition to Masimo's Board. Her deep expertise from decades spent in relevant roles at Johnson & Johnson, in addition to her experience as a public company director, make her an ideal fit to help Masimo. The opportunity to do so is why she is participating in this election. Michelle wants to be able to bring the type of positive, substantive improvement to the Company that has been outlined in Politan's campaign and will only be possible with a real level of change. If elected, Michelle and I will be fully committed from day one to working constructively alongside the other directors to further the best interests of the Company. While we unfortunately expect the emotive attacks from Masimo to continue leading up to the vote, we encourage shareholders to look past these unproductive distractions. We believe the facts and analysis we have presented - all of which are carefully supported - speak for themselves. We look forward to continuing to engage with our fellow shareholders in the weeks ahead."

16:41 EDT Spectrum Brands gets clearance from Mexico to sell HHI segment - Spectrum Brands )SPB) announced that it has received clearance from the Mexican competition authority to sell the Company's Hardware and Home Improvement segment ,"HHI", to ASSA ABLOY (ASAZY) for $4.3B in cash, subject to customary adjustments. The approval from the Mexican competition authority was the last regulatory approval required to complete this transaction. The closing of this transaction is subject to satisfaction of customary closing conditions. The Company continues to expect to close this transaction on or prior to June 30, 2023.

16:31 EDT Children's Place expands revolving credit facility to $445M - The Children's Place announced the expansion of its revolving credit facility from $350 million to $445 million. Sheamus Toal, CFO, said, "We are extremely pleased to welcome PNC Bank as a new joint lead arranger, who is committing an additional $95 million toward our revolving credit facility and we are grateful for the support provided by our current banking group. This additional credit availability will significantly strengthen our financial position while also supporting our seasonal working capital needs and investments in the Company's future growth."

16:29 EDT Dish director James Defranco buys 300,000 class A shares - In a regulatory filing, Dish Network director James Defranco disclosed the acquisition of 300,000 class A common shares of the company at a price of $6 per share.

16:20 EDT TeraWulf self mines 323 bitcoin in May - The company self-mined 323 bitcoin in May with an average production rate of 10.4 bitcoin per day. "The increase in our hash rate this month coupled with a temporary spike in transaction fees due to the emergence of Ordinals on the blockchain more than offset May's increase in network difficulty, enabling the Company to deliver a 35% month-over-month increase in bitcoin produced," stated Kerri Langlais, chief strategy officer of TeraWulf. "Additionally, with a realized average cost of power of less than $0.03 per kilowatt hour and average availability in excess of 98% in May, we steadily increased profit margins month over month despite challenging market conditions," added Langlais. As of May 31, the company had an operational miner fleet of approximately 36,000 of the latest generation miners, comprised of 20,000 miners at its wholly owned Lake Mariner facility in New York and 16,000 self-miners at the nuclear-powered Nautilus facility in Pennsylvania.

16:17 EDT Univar names Alexandra Colin as General Counsel - Univar Solutions (UNVR) named Alexandra Colin as General Counsel effective July 1. In this role, Colin will serve as chief legal advisor and lead global compliance and enterprise risk management programs for the company. Colin joins Univar Solutions after serving as associate general counsel, personal care North America for Kimberly-Clark (KMB).

16:15 EDT HTG Molecular trading resumes

16:12 EDT Broadstone Net Lease says portfolio collected 100% of base rents in April-May - The company states that it "collected 100% of base rents due through April and May for all properties under lease, and as of the date of this release our portfolio was 99.4% leased based on rentable square footage as of the end of the first quarter, with two of our total properties vacant and not subject to a lease... During the second quarter, we sold four properties for proceeds of $69.4 million at a weighted average cap rate of 5.6% on tenanted properties."

16:10 EDT Nevro names Greg Siller as Chief Commercial Officer - Nevro announced that Greg Siller has been appointed Senior Vice President and Chief Commercial Officer of Nevro, effective June 19. Siller replaces Niamh Pellegrini, who will be leaving the organization effective June 9. The company also announced that in conjunction with this appointment, it is updating its revenue guidance for the second quarter of 2023 to a range of $106M-$108M and plans to update its annual guidance when it reports its second quarter 2023 financial results.

16:08 EDT Precigen announces 'positive' Phase 1 data for PRGN-3005 UltraCAR-T - Precigen presented positive data at the 2023 American Society of Clinical Oncology Annual Meeting from the Phase 1 portion of the Phase 1/1b clinical study evaluating safety and efficacy of PRGN-3005 UltraCAR-T in advanced stage platinum resistant ovarian cancer patients. The presentation was delivered by John B. Liao, MD, PhD, Cancer Vaccine Institute, University of Washington Medicine, and a lead investigator for the PRGN-3005 clinical trial. "We are pleased with the results of the Phase 1 study which demonstrate a favorable safety profile for PRGN-3005 UltraCAR-T. Our UltraCAR-T therapies continue to be well-tolerated with no dose limiting toxicities across our clinical stage UltraCAR-T portfolio," said Helen Sabzevari, PhD, President and CEO of Precigen. "At this early stage, we are encouraged that patients in the IV plus lymphodepletion arm showed stable or partial response in 90% of the individual target lesions, and that the case study presented demonstrated that the repeat dosing further decreased tumor burden. UltraCAR-T is the only CAR-T platform that has demonstrated the ability to expand and persist and show a reduction in tumor burden and lesions with low doses of UltraCAR-T cells in this heavily pretreated ovarian cancer patient population. We are currently underway in the Phase 1b dose expansion study at Dose Level 3 via IV infusion with lymphodepletion and incorporating repeat dosing."

16:07 EDT CBIZ acquires Pivot Point Security, terms not disclosed - CBIZ announced that it has acquired information security consulting firm, Pivot Point Security, of Hamilton, NJ, effective June 1, 2023. Founded in 2001, PPS helps small and middle market businesses navigate the complex challenges of information security and compliance. PPS has 30 employees and recorded $6.6M in revenue in 2022.

16:06 EDT Ultragenyx & Mereo BioPharma announce data on Orbit study of setrusumab in OI - Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma Group (MREO) announced data from the dose-selection Phase 2 portion of the Phase 2/3 Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients. Across all patients evaluated setrusumab demonstrated statistically significant increases in levels of serum P1NP, a sensitive marker of bone formation, and a substantial and significant improvement in bone mineral density BMD by 3 months "The rate of increasing bone mineralization we're observing on DXA scans is striking, unlike anything I have typically seen with bisphosphonate therapy. This increase in bone mass underscores the potential to make denser and stronger bone," said Gary Gottesman, M.D., Professor of Pediatrics and Medicine, Washington University School of Medicine..."The dramatic lumbar spine BMD improvements in children at 3 months show that growing bones are more dynamic, and we anticipate the potential for a greater effect on bone formation and strength in younger patients with maturing bones," said Eric Crombez, M.D., chief medical officer at Ultragenyx. "Based on the reports from study investigators, we're encouraged by the impact setrusumab appears to be having on bone health so far." As of the data cut-off, there have been no treatment-related serious adverse events observed in the study. Reported adverse events have been generally consistent with those observed in the ASTEROID study and include infusion associated events, headache and sinusitis. There have been no reported hypersensitivity reactions related to setrusumab. There were no safety-related differences observed between dosing groups or age groups. The totality of data demonstrated meaningful response in serum P1NP and BMD across both cohorts, with the majority of the effect observed at 20 mg/kg, which is the dose planned across the setrusumab Phase 3 program. Screening has begun for the Phase 3 portion of the study, which is designed to enroll approximately 195 patients at more than 40 sites across 12 countries.

16:00 EDT LiveWire names Karim Donnez CEO - LiveWire Group announced the appointment of Karim Donnez as Chief Executive Officer, effective June 12, 2023. Donnez will succeed current CEO Jochen Zeitz who, having served as CEO for an agreed period, will remain as Chairman of LiveWire Group, Inc. Jochen Zeitz, Chairman and CEO, LiveWire, and Chairman, President, and CEO of Harley-Davidson, said: "Having successfully stood-up LiveWire as a brand and listed the Company on the NYSE, I'm excited to pass the baton to Karim and to welcome him as LiveWire's new CEO, following an extensive global search process. Karim is an entrepreneurial business leader with a demonstrable track record of driving transformational growth through both strategy development and implementation. The Board and I look forward to Karim realizing the potential of LiveWire, as we continue on the Company's journey to lead the electrification of the sport." Prior to joining BRP, Donnez held leadership positions at Rio Tinto, most recently as General Manager, Refinery & Energy for Rio Tinto Kennecott, where he oversaw business transformation initiatives as part of corporate global functions. Donnez started his career at Accenture.

15:48 EDT HTG Molecular files voluntary petition for relief under Chapter 11 - According to a regulatory filing, on June 5, 2023, HTG Molecular Diagnostics filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The company will operate its business as a "debtor-in-possession" under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. To facilitate its ability to continue operating in the ordinary course of business, the Company has filed with the Court motions seeking a variety of "first-day" relief. Additional information about the Case, including access to Court documents, is available from the Court, via the office of the clerk. The filing of the Case constituted an event of default that accelerated all of the Company's obligations under the Company's Loan and Security Agreement, dated June 24, 2020, as amended, with Silicon Valley Bank, N.A., a division of First-Citizens Bank and Trust Company, comprising an outstanding principal amount of $2,687,255, together with accrued interest and all applicable fees and other financial obligations.

15:35 EDT SunCar Technology Group Inc trading halted, volatility trading pause

15:06 EDT Apple unveils Vision Pro 'spatial computer,' starting at $3,499 - Apple unveiled Apple Vision Pro, which it calls "a revolutionary spatial computer that seamlessly blends digital content with the physical world, while allowing users to stay present and connected to others." Apple stated: "Vision Pro creates an infinite canvas for apps that scales beyond the boundaries of a traditional display and introduces a fully three-dimensional user interface controlled by the most natural and intuitive inputs possible - a user's eyes, hands, and voice. Featuring visionOS, the world's first spatial operating system, Vision Pro lets users interact with digital content in a way that feels like it is physically present in their space. The breakthrough design of Vision Pro features an ultra-high-resolution display system that packs 23 million pixels across two displays, and custom Apple silicon in a unique dual-chip design to ensure every experience feels like it's taking place in front of the user's eyes in real time." Tim Cook, Apple's CEO, added: "Today marks the beginning of a new era for computing. Just as the Mac introduced us to personal computing, and iPhone introduced us to mobile computing, Apple Vision Pro introduces us to spatial computing. Built upon decades of Apple innovation, Vision Pro is years ahead and unlike anything created before - with a revolutionary new input system and thousands of groundbreaking innovations. It unlocks incredible experiences for our users and exciting new opportunities for our developers." Apple Vision Pro starts at $3,499 U.S. and will be available early next year at Apple Store locations in the U.S., with more countries coming later next year, Apple stated.

15:04 EDT S&P Ratings upgrades Walt Disney Co. to 'A-' - S&P Global Ratings raised its ratings on Disney, including the issuer credit rating, to 'A-' from 'BBB+'. S&P stated: "Disney is on a path to lowering S&P Global Ratings-adjusted leverage to 3x by the end of fiscal 2023. Disney ended its most recent quarter, second-quarter fiscal 2023, which ended April 1, 2023, with S&P Global Ratings-adjusted leverage of 3.3x. We forecast that leverage will decline to 3x by the end of fiscal 2023 and could decline below 2.5x in fiscal 2024. This leverage reduction will result from significant growth in Disney's EBITDA and cash flow over the next two years as losses at the DTC business segment lessen, earnings at its Disney Parks, Experiences, and Products business segment improve, and the company realizes over $5.5 billion in cost savings from ongoing cost-cutting initiatives."

15:02 EDT Fury Gold Mines halts work at Eau Claire following fire evacuation order - Fury Gold Mines Limited announces that the company has paused all exploration activities at its Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec following an emergency fire evacuation order. On June 4, the Minister of Natural Resources mandated that all mining exploration activities stop immediately, all personnel be evacuated from the territory, and that helicopters and aircraft be made available to help fight fires and carry out emergency evacuations. Following notice from the Crown, Fury has temporarily halted exploration activities and has begun evacuating crews from the Eau Claire site. The company will continue to monitor the situation as it progresses. "As wildfires continue to threaten parts of the James Bay area, we are following the direction of local authorities and prioritizing the safety of our team. We are thinking of the communities and their members who are impacted by the fires in northern Quebec. We look forward to returning to work at Eau Claire shortly," commented Tim Clark, CEO of Fury.

15:00 EDT Unity Software trading halted, volatility trading pause

14:59 EDT Apple working with Unity to bring apps to Vision Pro

14:56 EDT Apple says Vision Pro comes with new chip called R1

14:44 EDT Disney+ to be available on Apple Vision Pro on day one

14:40 EDT Apple says Vision Pro comes with game controller support - Says Vision Pro allows for 3D movies.

14:27 EDT Apple announces iOS 17 with updates to Phone, FaceTime and Messages - Apple announced iOS 17, which it calls "a major release that upgrades the communications experience across Phone, FaceTime, and Messages; makes sharing even easier with AirDrop; and provides more intelligent input that improves the speed and accuracy of typing." Apple stated that iOS 17 also introduces new experiences with Journal, an app that makes it easy for people to practice gratitude, and StandBy, a new way to view glanceable information when iPhone is set down and charging. "With iOS 17, we've made iPhone more personal and intuitive by deeply considering the features we all rely on every day. Phone, FaceTime, and Messages are central to how we communicate, and this release is packed with updates we think our users are going to love. We've also reimagined AirDrop with new ways to share, autocorrect gets even better, and we're introducing all-new experiences with Journal and StandBy, plus so much more. We can't wait for everyone to try it," said Craig Federighi, Apple's senior vice president of Software Engineering. The developer beta of iOS 17 is available to Apple Developer Program members today, and a public beta will be available next month. New software features will be available this fall as a free software update for iPhone XS and later.

14:25 EDT Apple announces tvOS 17 for Apple TV - Apple announced software updates coming this fall for Apple TV 4K. With tvOS 17, FaceTime comes to Apple TV 4K, so users can enjoy the popular app on their TV for even more engaging conversations with family and friends. tvOS 17 also introduces an all-new Control Center, along with other enhancements that provide a more personalized experience that works even better with iPhone. Apple TV 4K brings together Apple TV+ and all of the most popular streaming apps, as well as Apple Music, Apple Fitness+, and Apple Arcade to the biggest screen in the home. tvOS 17 is available as a developer beta immediately, and it will be available as a free software update this fall. "tvOS 17 transforms the biggest screen in the home with FaceTime and new video conferencing capabilities, giving Apple TV 4K users the ability to easily connect with anyone right from their living room," said Bob Borchers, Apple's vice president of Worldwide Product Marketing. "New features and enhancements make Apple TV simpler to use and even more enjoyable, reinforcing it as the absolute best option in the living room for Apple customers."

14:24 EDT Apple says users control Vision Pro with eyes, hands, voice - Says surroundings become "infinite canvas" with Vision Pro.

14:23 EDT Apple announces watchOS 10 for Apple Watch - Apple previewed watchOS 10, bringing Apple Watch users a "fresh approach to quickly view information with redesigned apps, a new Smart Stack to show relevant widgets right when they're needed, and delightful new watch faces." New metrics, Workout Views, and Bluetooth connectivity for power meters, speed sensors, and cadence sensors arrive for cyclists, while new Compass Waypoints and Maps capabilities further help hikers. The Mindfulness app offers additional tools to support mental health. watchOS 10 is available as a developer beta immediately, and will be available as a free software update this fall. "watchOS is the world's most advanced wearable operating system, and it has redefined how people all over the world think of what a watch can do," said Kevin Lynch, Apple's vice president of Technology. "watchOS 10 is a major milestone and an energizing new approach for Apple Watch, introducing a fresh new design for quickly viewing information, delightful new watch faces, new features for cyclists and hikers, and important tools for health."

14:22 EDT Apple unveils new mixed reality headset Apple Vision Pro

14:21 EDT Apple says new OS releases available to users this Fall

14:12 EDT Apple says WatchOS comes with new Cycling features - Says new Apple Watch can now connect to Bluetooth-enabled power sensors.

14:08 EDT Apple unveils Apple WatchOS 10

14:03 EDT Apple says bringing iPhone SharePlay to cars

14:02 EDT Lumen Technologies trading resumes

13:54 EDT Binance says SEC enforcement action 'unjustified' - Binance issued a statement in response to the SEC complaint made public today, stating in part: "Today's action by the U.S. Securities and Exchange Commission (SEC) comes after extensive cooperation and recent good-faith negotiations. We are disappointed that the SEC chose to file a complaint today against Binance seeking, among other remedies, purported emergency relief. We now join a number of other crypto projects facing similarly misguided actions from the SEC and we will vigorously defend our business and the industry. We want to be clear that while we take the allegations in the SEC's complaint seriously, they should not be the subject of an SEC enforcement action, let alone on an expedited basis. They are unjustified. From the start, we have actively cooperated with the SEC's investigations and we have engaged in good-faith discussions to reach a negotiated settlement to resolve those investigations. The SEC's suit today demonstrates their recalcitrance to engage with us substantively to resolve such concerns. Today, despite our efforts at productive engagement, the SEC abandoned and denied us due process, and instead unilaterally chose to litigate. We respectfully disagree with the SEC's allegations that Binance operated as an unregistered securities exchange or illegally offered and sold securities, including by offering BNB, or the BUSD fiat-backed stable coin... Further, although it is at this time unclear whether the SEC will follow through, the SEC's complaint suggests a desire to seek emergency relief in the future. There is no valid basis on which the SEC would be entitled to emergency relief... Because of our size and global name recognition, Binance has found itself an easy target caught in the middle of a U.S. regulatory tug-of-war. The SEC's own actions throughout this matter reveal its hasty approach to this investigation... The SEC's unreasonable and unfair approach has left us with no choice but to defend our business... We want to reiterate: although this glaring lack of process and cooperation is frustrating, what is most concerning to us is the fact that the SEC appears to have given no consideration to the drastic and cascading negative impact its actions today may have on users and the industry. User security has always been paramount to Binance, and although we will do everything we can to continue to provide that security to our users, any subsequent ripple effects through the platform and the industry will be directly attributable to the SEC's unjustified decision to unilaterally litigate on a purported emergency basis today. The SEC's choice is disheartening for Binance, its users, and the industry as a whole. However, this action will not stop us from continued robust collaboration with other regulators and policymakers across the globe, and we will continue to vigorously defend our business and this technology."

13:52 EDT Kojima Productions 'actively working' to bring future titles to Apple platforms

13:45 EDT Apple unveils macOS Sonoma - Says new features on iOS and iPadOS will be "great" on macOS.

13:42 EDT Apple says iPadOS 17 can identify fields in a PDF for auto-filling

13:40 EDT Lumen Technologies trading halted, news pending

13:38 EDT Apple unveils iPadOS 17 - Says bringing lockscreen experience to iPad.

13:32 EDT Titan Medical announces asset purchase and license agreement with Medtronic - Titan Medical (TMDIF) announced that the company has entered into an asset purchase and license agreement with Medtronic (MDT) for an upfront payment of $8.0M in respect of certain intellectual property, or "IP," of Titan. Under the terms of the agreement, Titan has sold to Medtronic the patents previously exclusively licensed by Titan to Medtronic under a license agreement dated June 3, 2020 and under a development and license agreement dated June 3, 2020, and granted Medtronic a non-exclusive license to certain other Titan intellectual property, excluding the acquired rights. Medtronic has granted Titan a limited non-exclusive license back to the acquired rights and Titan retains ownership of the licensed IP, along with the associated rights including the right to continue to develop and commercialize the technologies covered by the licensed IP and the right to further license the licensed IP to other third parties, Titan stated.

13:30 EDT Apple unveils enhanced Autocorrect features - Says updated Autocorrect now leverages tranformer model in Messages keyboard. Says new Autocorrect now has more accurate dictation engine and better, more personalized predictive text.

13:26 EDT Notable companies reporting after market close - Notable companies reporting after the market close, with earnings consensus, include GitLab (GTLB), consensus (14c)... Sprinklr (CXM), consensus 1c.

13:19 EDT Apple unveils MacBook Air, 'the world's best 15-inch laptop' - Apple introduced the 15-inch MacBook Air, which it dubs "the world's best 15-inch laptop." Apple stated: "With an expansive 15.3-inch Liquid Retina display, the incredible performance of M2, up to 18 hours of battery life, and a silent, fanless design, the new MacBook Air brings power and portability - all in the world's thinnest 15-inch laptop. With an all-new six-speaker sound system, the 15-inch MacBook Air delivers immersive Spatial Audio, along with a 1080p FaceTime HD camera, MagSafe charging, and the power and ease of macOS Ventura for an unrivaled experience. Customers can order starting today, with availability beginning Tuesday, June 13. The 13-inch MacBook Air with M2 gets a new starting price of $1,099 - $100 less than before - to deliver even more value and choice to everyone, from upgraders to first-time Mac customers."

13:18 EDT Apple introduces M2 Ultra - Apple announced M2 Ultra, a new system on a chip "that delivers huge performance increases to the Mac and completes the M2 family. M2 Ultra is the largest and most capable chip Apple has ever created, and it makes the new Mac Studio and Mac Pro the most powerful Mac desktops ever made. M2 Ultra is built using a second-generation 5-nanometer process and uses Apple's groundbreaking UltraFusion technology to connect the die of two M2 Max chips, doubling the performance." "M2 Ultra delivers astonishing performance and capabilities for our pro users' most demanding workflows, while maintaining Apple silicon's industry-leading power efficiency," said Johny Srouji, Apple's senior vice president of Hardware Technologies. "With huge performance gains in the CPU, GPU, and Neural Engine, combined with massive memory bandwidth in a single SoC, M2 Ultra is the world's most powerful chip ever created for a personal computer."

13:15 EDT Apple unveils Mac Pro with Apple Silicon - Says new Mac Pro comes with M2 Ultra chip.

13:10 EDT Apple says new Macbook Air starts at $1,299, available next week - Apple (AAPL) says new Macbook Air has 1080p camera, a new mic array, and improved sound quality with spatial audio. Says Macbook Air powered by new M2 chip. Says Air 12x fastest than fantest Intel-based (INTC) Macbook Air. Says 13-inch MacBook Air with M2 now starts at $1,099.

13:03 EDT Janssen presents longer-term data for Tecvayli - The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing the sustained efficacy and safety of Tecvayli in the treatment of patients with relapsed or refractory multiple myeloma who are triple-class exposed and previously received treatment with three or more prior lines of therapy. These results showed that nearly half of patients achieved a complete response or better, which underscore the continued durable responses seen in this patient population, the company stated. These data were featured at the 2023 American Society of Clinical Oncology, or ASCO, Annual Meeting along with additional poster presentations from MajesTEC-1 featuring data on the durability of responses with Tecvayli biweekly dosing as well as an evaluation of the use of tocilizumab, given prophylactically, to examine potential reduction of cytokine release syndrome in the management of RRMM patients treated with Tecvayli. Extended follow-up data from the pivotal Phase 1/2 MajesTEC-1 study of Tecvayli demonstrate an overall response rate, or ORR, of 63%, with responses that continued to deepen over time. More than 45% of patients have now achieved a CR or better, and median time to CR or better was 4.6 months. The minimal residual disease negativity rate by Day 100 from first dose of Tecvayli in evaluable patients was 81%.

12:34 EDT Gilead: Trodelvy delivered meaningful improvement in median OS in study - Gilead Sciences announced longer-term overall survival results from the Phase 3 TROPiCS-02 study evaluating Trodelvy versus comparator chemotherapy in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinically meaningful improvement in median OS benefit compared to TPC. These findings will be shared as an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting. "These longer-term results show the durable overall survival benefit of sacituzumab govitecan over traditional chemotherapy in pre-treated HR+/HER2- metastatic breast cancer," said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. Progression-free survival rates for Trodelvy vs. TPC were consistently higher at landmark milestones of 6, 12 and 18 months, Gilead said. Similarly, OS rates for Trodelvy vs. TPC were consistently higher at landmark milestones of 12, 18, and 24 months. Ninety-two percent of patients in TROPiCS-02 were also eligible for evaluation of OS by HER2 status, as measured by immunohistochemistry. Patients treated with Trodelvy demonstrated improved OS versus TPC in both the HER2 IHC0 and HER2-low groups. Trodelvy was approved in February 2023 by the U.S. Food and Drug Administration for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The European Medicines Agency has also validated a Type II Variation Marketing Authorization Application for Trodelvy in HR+/HER2- metastatic breast cancer.

12:25 EDT Penske Automotive acquires Transolutions Truck Centres, terms not disclosed - Penske Automotive Group announced that it has acquired Transolutions Truck Centres, a retailer of medium and heavy-duty commercial trucks and buses, located in Winnipeg, Manitoba, Canada. With this acquisition, Premier Truck Group, the company's wholly-owned commercial truck subsidiary, continues to expand and complement its operations in Canada by establishing a presence in an additional Canadian province. TSTC consists of five locations throughout the greater Winnipeg market, including three full-service dealerships and two parts & service centers. TSTC sells and services Freightliner Trucks, Western Star Trucks and Thomas Built Buses, and is the licensed dealer for SelecTrucks, Daimler Truck's used vehicle brand, for the entire territory of Manitoba. The TSTC acquisition is expected to add 73 service bays, 59 technicians and approximately 200 new members to the Premier Truck Group team. The acquisition is expected to generate approximately $180M in annualized revenue. With the inclusion of the TSTC facilities, Premier Truck Group now operates 44 locations throughout North America. Commenting on the acquisition, Premier Truck Group President Ron Long said, "We are thrilled to expand our North American presence with the Freightliner, Western Star and Thomas Built Bus brands. For more than 30 years, Transolutions Truck Centers has built a strong legacy of providing quality service to customers across Manitoba. We look forward to continuing their legacy and welcome TSTC to the Premier Truck Group team."

12:02 EDT PGT Innovations acquires 25% remaining ownership interest in Eco Enterprises - PGT Innovations has acquired the remaining outstanding 25% ownership interest in Eco Enterprises, a brand of aluminum, impact-resistant windows and doors primarily serving the south Florida region, with manufacturing and glass processing facilities in Miami, FL. PGT Innovations first acquired 75% ownership stake in Eco in 2021 to accelerate revenue growth, expand margins, and strengthen supply chain by adding glass production capacity, while diversifying and bolstering product lines to provide opportunities in residential and commercial markets.

12:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -9.7% - ProShares UltraShort Bloomberg Natural Gas is down -9.7%, or -$8.59 to $80.31.

12:00 EDT Epam Systems falls -18.1% - Epam Systems is down -18.1%, or -$47.05 to $212.59.

12:00 EDT Getty Images rises 21.2% - Getty Images is up 21.2%, or $1.01 to $5.77.

11:55 EDT Publicis acquires Corra, terms not disclosed - Publicis announced the acquisition of Corra, an ecommerce company in North America. Corra will become part of Publicis Sapient, Publicis Groupe's digital business transformation company, and will augment Publicis Sapient's existing expertise in commerce solutions, including Adobe Commerce and MACH Alliance composable commerce solutions, while extending Publicis Sapient's offerings in digital and omnichannel commerce. In addition, Corra will bring dedicated resources that span many of Publicis Sapient's SPEED (Strategy, Product, Experience, Engineering and Data & AI) capabilities. The Corra team will join Publicis Sapient, with CEO Ron Bongo and co-owners CTO Michael Harvey and President Rachel Weir reporting into the company's Commerce practice leadership. "The acquisition of Corra marks a continuation of our strategic investment in the dynamic commerce space," said Arthur Sadoun, Chairman and CEO of Publicis Groupe. "Alongside the digital business transformation capabilities of Publicis Sapient and the impressive Adobe commerce suite, Corra only further accelerates our unique ability to connect brands via industry-leading technology services and solutions." The terms of the deal were not disclosed.

11:39 EDT SEC files 13 charges against Binance entities and founder Changpeng Zhao - The Securities and Exchange Commission charged Binance Holdings Ltd., which operates the largest crypto asset trading platform in the world, Binance.com; U.S.-based affiliate, BAM Trading Services Inc., which, together with Binance, operates the crypto asset trading platform, Binance.US; and their founder, Changpeng Zhao, with a variety of securities law violations. Among other things, the SEC alleges that, while Zhao and Binance publicly claimed that U.S. customers were restricted from transacting on Binance.com, Zhao and Binance in reality subverted their own controls to secretly allow high-value U.S. customers to continue trading on the Binance.com platform. Further, the SEC alleges that, while Zhao and Binance publicly claimed that Binance.US was created as a separate, independent trading platform for U.S. investors, Zhao and Binance secretly controlled the Binance.US platform's operations behind the scenes. "Through thirteen charges, we allege that Zhao and Binance entities engaged in an extensive web of deception, conflicts of interest, lack of disclosure, and calculated evasion of the law. As alleged, Zhao and Binance misled investors about their risk controls and corrupted trading volumes while actively concealing who was operating the platform, the manipulative trading of its affiliated market maker, and even where and with whom investor funds and crypto assets were custodied. They attempted to evade U.S. securities laws by announcing sham controls that they disregarded behind the scenes so that they could keep high-value U.S. customers on their platforms. The public should beware of investing any of their hard-earned assets with or on these unlawful platforms," said SEC Chair Gary Gensler. The SEC also alleges that Zhao and Binance exercise control of the platforms' customers' assets, permitting them to commingle customer assets or divert customer assets as they please, including to an entity Zhao owned and controlled called Sigma Chain. Publicly traded companies in the cryptocurrency space include Bit Digital (BTBT), Coinbase (COIN), Core Scientific (CORZ), Greenidge Generation (GREE), Marathon Digital (MARA), MicroStrategy (MSTR), Riot Platforms (RIOT), Stronghold Digital Mining (SDIG) and TeraWulf (WULF). Reference Link

11:28 EDT Kite's Yescarta CAR T-cell therapy shows longer OS vs. SOC in study - Kite, a Gilead Company, announces detailed results from the overall survival analysis of the landmark Phase 3 ZUMA-7 study of Yescarta CAR T-cell therapy compared with historical standard of care as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma. Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population. The late-breaking data are being presented orally at the 2023 American Society of Clinical Oncology Annual Meeting and published simultaneously in the New England Journal of Medicine. With a median follow-up of 4 years, a one-time treatment with Yescarta demonstrated significantly longer overall survival compared to SOC with a 27.4% reduction in the risk of death, which corresponds to a 38% relative improvement in overall survival, for patients with R/R LBCL within 12 months completion of first-line therapy. "As the first treatment in nearly three decades to significantly improve survival for patients with relapsed/refractory large B-cell lymphoma, axi-cel can potentially change the standard of care for these patients who previously had very limited options for successful curative therapy," said Jason Westin, MD, MS, FACP, ZUMA-7 Principal Investigator, Director, Lymphoma Clinical Research, and Associate Professor, Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center. "The totality of the ZUMA-7 data provides a compelling case for axi-cel to be used as soon as patients with large B-cell lymphoma do not respond to or relapse from first-line treatment."

11:16 EDT FDA revokes EUA for J&J's Covid-19 vaccine - The FDA said last week: "On May 22, 2023, Janssen Biotech, Inc. requested the voluntary withdrawal of the emergency use authorization of the Janssen COVID-19 Vaccine. Janssen Biotech, Inc. informed the FDA that the last lots of the vaccine purchased by the U.S. Government have expired, there is no demand for new lots of the vaccine in the U.S., and they do not intend to update the strain composition of this vaccine to address emerging variants. On June 1, 2023, FDA revoked the EUA for this vaccine." Reference Link

11:12 EDT Janssen announces results from Phase 3 CARTITUDE-4 study of Carvykti - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that results from the Phase 3 CARTITUDE-4 study showed Carvykti reduced the risk of disease progression or death by 74% compared to two standard of care treatment regimens, pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone, in adults with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy. These data were featured in the press program and as an oral presentation in a special session at the 2023 American Society of Clinical Oncology, or ASCO, Annual Meeting and were simultaneously published in The New England Journal of Medicine. The results will also be presented at the European Hematology Association Hybrid Congress as part of the plenary session on Saturday, June 10. The CARTITUDE-4 study is the first randomized study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma, the company noted. The Phase 3 CARTITUDE-4 study included patients who received one to three prior lines of therapy, including a proteasome inhibitor and immunomodulatory agent, and were lenalidomide-refractory. Patients were randomized, and those in the Carvykti arm then underwent apheresis. In the Carvykti arm, 50% of patients were refractory to treatment with a PI and 23 percent were refractory to treatment with anti-CD38 therapies; in the SOC group, 46 percent and 21 percent of patients were refractory to PI and anti-CD38 therapies, respectively. 33% of patients in the Carvykti group received one prior line of treatment, compared to 32% of patients in the SOC group.

10:36 EDT Wipro provides further details regarding buyback offer - Wipro Limited issued a public announcement in India providing further details regarding the buyback by the company of up to 269,662,921 fully paid-up equity shares of face value Rs. 2/- each of the company representing up to 4.91% of the total number of equity shares in the paid-up equity share capital of the company at a price of Rs. 445/- , or $5.421 per equity share payable in cash for an aggregate amount of up to Rs. 120,000,000,000/-. "The Buyback Size constitutes 20.95% and 17.86% of the aggregate of the fully paid-up Equity Share capital and free reserves of the Company as per the latest audited standalone and consolidated balance sheet, respectively, as at March 31, 2023. The Buyback will be conducted on a proportionate basis through the "tender offer" route as prescribed under the Securities and Exchange Board of India Regulations, 2018, as amended, and the Indian Companies Act, 2013, as amended, and rules made thereunder, including any statutory modifications or re-enactments thereof, from all holders of Equity Shares who hold Equity Shares as of Friday, June 16, 2023, the record date for the Buyback. The Buyback Size does not include any transaction costs viz. brokerage, applicable taxes such as Buyback tax, securities transaction tax, GST, stamp duty, expenses incurred or to be incurred for the Buyback like filing fees payable to the Securities and Exchange Board of India, advisors/legal fees, public announcement publication expenses and other incidental and related expenses, etc. Buyback tax does not form part of the Buyback Size and will be appropriated out of the free reserves of the Company. The Company's American Depositary Shares, or 'ADSs,' each representing one Equity Share, evidenced by American Depositary Receipts, or 'ADRs,' are traded in the U.S. on the New York Stock Exchange under the ticker symbol 'WIT.' In order for a holder of ADSs to participate in the Buyback, such holder will need to become a direct shareholder of the Company prior to the Record Date," the company stated.

10:19 EDT NestEgg completes strategic financing round - Nest Egg announced its latest round of financing, led by partners OceanFirst Bank and Republic Bancorp, Inc., as well as other strategic investors. Nest Egg's strategic funding will support the company in expanding its investment platform presence across the United States. Currently partnered with 11 financial institutions, Nest Egg services are accessible to nearly 1 million bank customers at over 100 locations in 12 states. Nest Egg is slated to finalize several new partnerships in 2023, continuing momentum gained in 2022 and early 2023.

10:17 EDT Blackbaud announces new wave of Intelligence for Good strategy - Blackbaud announced the launch of a major new wave of its Intelligence for Good strategy, with an extensive agenda of initiatives and investments to be implemented on a rolling basis over upcoming quarters targeted at making artificial intelligence more accessible, powerful and responsible across the social impact sector. While committing to the continued enhancement of existing features like AI-enabled prospecting and intelligent donation forms, Blackbaud will expand into new areas including automated generation of stewardship documents and assisted learning targeted at driving an exponential increase in the productivity of social impact organizations. At the heart of Blackbaud's next-generation AI strategy is a commitment to make AI more accessible to social impact organizations by providing complete, ready-made solutions that address specific challenges related to the optimization of fundraising, stewardship, corporate impact and education needs. Specifically, Blackbaud plans to announce an extensive set of new capabilities in 2023, including: AI for Peer-to-Peer Fundraisers: Enabling P2P participants to use Generative AI-based features to make sharing their own story easier and more effective for their fundraiser. AI for Online Giving: Providing a personalized experience to online donors through predictive AI capabilities. AI for Major Giving Officers: Expanding Prospect Insights to include AI-driven insights into planned and major giving vehicles and likelihood. AI for Donor Stewardship: Enabling organizations to automate the creation of key donor stewardship documents such as thank you notes through a built-in Generative AI experience. AI for Educators: Assisting teachers with personalized, AI-driven content that has appropriate guardrails to drive more classroom engagement. AI for School Administrators: Leveraging AI to automate review and recommendations of financial aid submissions. AI for Corporate Impact: Empowering Corporate Social Responsibility teams to capture, visualize and tell the story of their corporate social impact missions through inclusion of modern AI services. In addition to its increased investment in planned product enhancements to make AI more accessible to its customers, Blackbaud will accelerate the availability of partner solutions in the Blackbaud Marketplace. This includes nurturing and scaling an ecosystem of social impact-focused AI companies through its tech accelerator, the Social Good Startup Program.

10:12 EDT Tupperware Brands, Vera Bradley launch latest limited-edition collection - Tupperware (TUP) and Vera Bradley (VRA) announce the launch of their latest limited-edition product collaboration. Building on the success of the popular 2022 collection, the two brands are back with another line of must-have Tupperware food and drinkware containers featuring two of Vera Bradley's newest patterns: Sea Air Floral and Cloud Vine Multi. Each of the vibrant floral prints are available in a reusable ECO Water Bottle, Snack Set, and Sandwich Keeper.

10:10 EDT DLH Holdings Corp. trading resumes

10:05 EDT Tiziana reports reduction in microglial activation with intranasal foralumab - Tiziana Life Sciences announced a reduction in microglial activation as seen in 3-month Positron Emission Tomograpy scans that has now been seen in a total of 5 of the 6 patients with non-active secondary-progressive multiple sclerosis treated with intranasal foralumab in its Expanded Access program. Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer's disease and amyotrophic lateral sclerosis. A reduction in microglial activation is associated with lowered inflammation in the brain. Inflammation in the brain drives the disease pathology in multiple sclerosis. In SPMS, inflammation in the brain occurs in microglia, the brain's immune cells, which drive the neurodegeneration of brain cells. During the inflammatory process associated with SPMS, microglia are involved in the destruction of myelin, the protective sheath covering of nerve fibers, and contribute to the formation of MS lesions. Tarun Singhal, M.B.B.S., M.D., Director of PET Imaging Program in Neurologic Diseases, associate neurologist and nuclear medicine physician at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, and Assistant Professor of Neurology at Harvard Medical School, commented, "After review of the baseline and 3-month PET scans of the latest cohort of 4 Expanded Access patients, I have determined that 3 out of the 4 patients had a reduction in the microglial PET signal. When combined with my assessment of the first 2 Expanded Access patients, a total of 5 out of the 6 had a reduction in qualitative microglial PET signal, which appears to be clearly more significant than what we have identified in our test-retest assessments. I look forward to studying more patients, with full quantitation, and particularly, the next 4 patients in the Expanded Access program to see if this finding is replicated. We are preparing to submit the important results from this trial for publication."

10:02 EDT Innovation Pharmaceuticals says BeaMed reports progress in StingRay development - Innovation Pharmaceuticals informs shareholders that BeaMed reported significant progress in the development of its StingRay Laser system. BeaMed has completed the manufacturing of its first-ever MRI compatible fiber optic probes, marking a major technical milestone in its development of an advanced laser technology with respect to shaping energy and matching it to patient specific anatomy, a novel concept that BeaMed is proving a reality resulting in a major milestone in the advancement of the StingRay System. The completion of these probes allows for comprehensive integration tests, involving the unique MRI compatible fiber optics, an MRI interface software suite, special algorithms to simplify damage estimation, and custom insertion tools, planned to commence in late June 2023. An initial area of emphasis of the StingRay System will be for the treatment of epilepsy. Epilepsy affects millions of people worldwide, causing recurrent seizures that significantly diminish their quality of life. Traditional treatment methods, such as medication and surgery, possess limitations and may not be effective for all patients. Recognizing the critical need for innovation, BeaMed has developed an advanced laser system designed to revolutionize epilepsy treatment. The StingRay System, invented and developed by BeaMed, utilizes a cutting-edge laser-based thermal ablation technology specifically tailored for the treatment of previously inoperable cases of epilepsy. By employing state-of-the-art technology, this novel system precisely targets and ablates seizure-triggering brain tissues. Through controlled delivery of laser energy in a minimally invasive manner, the StingRay System offers enhanced precision and customization to address each patient's unique condition.

10:01 EDT Regencell Bioscience Holdings Ltd trading halted, volatility trading pause

10:00 EDT Arcus Biosciences falls -10.6% - Arcus Biosciences is down -10.6%, or -$2.22 to $18.79.

10:00 EDT Bowlero rises 7.7% - Bowlero is up 7.7%, or 89c to $12.49.

10:00 EDT Circor rises 49.7% - Circor is up 49.7%, or $15.75 to $47.42.

09:50 EDT Agenus presents 'positive' efficacy, safety outcomes for AGEN2373 at ASCO - Agenus presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 at the American Society of Clinical Oncology Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors. "AGEN2373 has shown meaningful single agent activity and a favorable safety profile without evidence of liver toxicity in patients with heavily pretreated cold and immunotherapy resistant tumors," said Dr. Steven O'Day, MD, Chief Medical Officer at Agenus. AGEN2373 was administered intravenously at doses ranging from 0.03 mg/kg to 10 mg/kg in a cohort of 46 patients with advanced solid tumors and a median of 4 prior lines of therapy. Notable responses in the dose escalation study include: Confirmed partial response in a patient with vulvar squamous cell carcinoma who progressed on prior pembrolizumab; Confirmed partial response with complete resolution of the pancreatic lesion in a patient with ampullary carcinoma; Confirmed 38% reduction in target liver lesions in a castrate-resistant prostate cancer that was non-evaluable by RECIST due to palliative radiation for bone metastases.

09:50 EDT Pasithea Therapeutics Corp trading resumes

09:47 EDT Tredegar falls -8.5% - Tredegar is down -8.5%, or -65c to $7.01.

09:47 EDT Epam Systems falls -17.2% - Epam Systems is down -17.2%, or -$44.65 to $215.00.

09:47 EDT DigitalBridge rises 6.6% - DigitalBridge is up 6.6%, or 85c to $13.69.

09:41 EDT Texas Southern University places $450,000 order with Knightscope - Knightscope announced that it received a $450,000 order for its K1 Blue Light Towers and K1 E-Phones. Texas Southern University is an existing customer that is purchasing an additional 39 devices consisting of 21 Blue Light Towers and 18 E-Phones.

09:40 EDT Cibus Global Inc trading resumes

09:31 EDT Zoom Video launches new features of Zoom IQ - Zoom Video Communications launched key features of Zoom IQ, a smart companion that empowers collaboration and unlocks people's potential through generative AI. Now available through free trials for customers in select plans,1 the Zoom Meeting summary and Zoom Team Chat compose features will help teams improve productivity, balance workday priorities, and collaborate more effectively. "With the introduction of these new capabilities in Zoom IQ, an incredible generative AI assistant, teams can further enhance their productivity for everyday tasks, freeing up more time for creative work and expanding collaboration," said Smita Hashim, chief product officer at Zoom. "There is no one-size-fits-all approach to large language models, and with Zoom's federated approach to AI, we are able to bring powerful capabilities to our customers and users through Zoom's own models as well as our partners' models."

09:30 EDT Cibus Global Inc trading halted, volatility trading pause

09:23 EDT NextSource Materials files amended, restated financial statements - NextSource Materials has filed amended and restated unaudited condensed interim financial statements and management's discussion and analysi for the nine and three months ended March 31, 2023, and 2022, which amends and restates the previously filed unaudited condensed interim financial statements and MD&A for the nine and three months ended March 31, 2023, and 2022. The Amended and Restated Financials and MD&A were filed due to an error in the estimation of the present value of the Right of Use Asset for the Mauritius BAF property lease, whereby the ending balances for Property, plant and development, and current and long-term lease obligations as at March 31, 2023 and the amortization and lease finance costs for the three and nine months ended March 31, 2023 were overstated. A security deposit was also reclassified from prepaid expenses to long-term deposits to reflect updated expectations. The MD&A was also modified to include enhanced disclosures regarding the BAF development projects and the use of non-IFRS terms.

09:20 EDT BK Technologies receives FCC approval for BKR 9000 multiband radio - BK Technologies announced that it has received approval from the Federal Communications Commission for the BKR 9000 multiband radio. The BKR 9000 radio is the Company's first multiband portable radio for the public safety market, providing high performance all-band coverage at a cost-efficient price point.

09:18 EDT RemeGen approved by Hong Kong Stock Exchange to remove B marker from stock name - RemeGen successfully obtained approval from The Stock Exchange of Hong Kong Limited on June 5, 2023 to remove the "B" marker from its stock short name as the Company's financial performance in 2022 met the market capitalization/revenue test under Rule 8.05(3) of the Hong Kong Stock Exchange's Listing Rules. This marks another significant milestone in RemeGen's development as it is transforming itself from a research-oriented biotech company to a fully-integrated biopharmaceutical company. Wang Weidong, RemeGen's chairman and executive director, said, "Despite facing a number of macro and industry headwinds in 2022, we nonetheless pushed ahead to make significant achievements that have led us to this approval from the Hong Kong Stock Exchange. Looking ahead, we expect momentum to continue both in China and around the globe in 2023 and beyond. We are well-positioned to accelerate growth and deliver strong shareholder returns while developing first-in-class and best-in-class products to help patients with unmet medical needs."

09:17 EDT Siyata Mobile announces $400,000 in new orders - Siyata Mobile announced that it has received new orders for its SD7 Handsets and VK7 Vehicle Kits totaling more than $400,000 in aggregate. The orders are expected to be delivered in the second quarter.

09:15 EDT Melcor Developments announces normal course issuer bid - Melcor Developments announced that the Toronto Stock Exchange has accepted its notice of intention to make a normal course issuer bid through the facilities of the TSX and on alternative trading systems. The notice provides that Melcor may, during the twelve-month period commencing June 7, 2023 and ending June 6, 2024, purchase for cancellation up to 1,562,431 common shares in total, being approximately 5% of its issued and outstanding common shares. The daily repurchase restriction for the common shares is 1,617. The price which Melcor will pay for any such common shares will be the market price at the time of acquisition. The actual number of common shares which may be purchased and the timing of any such purchases will be subject to compliance with the TSX guidelines. Under the previous normal course issuer bid, 1,641,627 common shares were purchased for cancellation through the facilities of the TSX at a weighted average price per common share of $11.88. Such repurchases represented the maximum number under the previous normal course issuer bid and were completed by December 23, 2022. As of May 29, 2023, there were 31,248,628 common shares of Melcor outstanding and the average daily trading volume for the six-month period ending April 30, 2023 was 6,469. Melcor believes that, at times, its common shares trade in a price range which does not adequately reflect the value of such common shares in relation to the business of Melcor and its future business prospects. As a result, depending upon future price movements and other factors, Melcor believes that its outstanding common shares may represent an attractive investment for itself. Furthermore, the purchases may benefit all persons who continue to hold common shares by increasing their equity interest in Melcor. All common shares purchased by Melcor under the normal course issuer bid will be cancelled. In connection with commencement of the NCIB the Corporation also announced that it has entered into an automatic share purchase plan agreement with a broker to allow for the purchase of common shares under the NCIB at times when the Corporation ordinarily would not be active in the market due to regulatory restrictions or self-imposed trading blackout periods. Before entering into such restricted or blackout period, the Corporation may, but is not required to, instruct the designated broker to make purchases under the NCIB in accordance with the terms of the ASPP. Such purchases will be determined by the broker in its sole discretion based on parameters established by the Corporation prior to the restricted or blackout period in accordance with TSX rules, applicable securities laws and the terms of the ASPP. Outside of these pre-determined restricted or blackout periods, common shares will be purchased based on management's discretion, in compliance with TSX rules and applicable securities laws.

09:13 EDT Brilliant Earth enters collaboration with Tracr - Brilliant Earth Group announced a new collaboration with Tracr, a digital platform for tracing natural diamonds from their source. The partnership will further unlock Brilliant Earth's blockchain-enabled natural diamond offerings, meeting the Company's ESG goal six months ahead of schedule.

09:13 EDT Sermonix shares ASCO poster presentation on ELAINE-2 study results - Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, broadly shared a poster presentation detailing the results of its ELAINE-2 clinical study with longer patient follow-up. The poster was initially presented yesterday at the 2023 American Society of Clinical Oncology Annual Meeting. ELAINE-2, an open-label, Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations study of Sermonix's lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company's CDK4/6 inhibitor abemaciclib, evaluated 29 women with ER+/HER2- locally advanced or metastatic breast cancer and an ESR1 mutation. The primary endpoint was safety/tolerability, with secondary endpoints including progression-free survival and overall response rate. Earlier ELAINE-2 results were shared at ASCO 2022. Lasofoxifene, which Sermonix licensed globally from Ligand Pharmaceuticals, has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide.

09:11 EDT Motorsport Games announces Le Mans Ultimate - In recognition of the FIA World Endurance Championship - the ultimate endurance racing challenge, cars representing the ultimate in technology, durability and performance, and taking place at the ultimate motorsport venue, there can only be one name for the official game for the 24 Hours of Le Mans and FIA WEC: Le Mans Ultimate. Expected in December 2023, this special centenary year for the Automobile Club de l'Ouest, owner and founder of the 24 Hours of Le Mans, the game has been developed by Motorsport Games' Studio 397 and will capture all the emotion, speed and glory of the world's most famous and prestigious endurance motorsport event. Studio 397, the developer behind the rFactor 2 platform, has a pedigree for gaming and sports car racing - with Studio 397 name reflecting the remarkable feat by Audi Sport in 2010, where its R15 prototype lapped the Circuit de la Sarthe 397 times before taking victory. The PC-based game will feature official cars and circuits from the 2023 FIA World Endurance Championship season, which, of course, has the 24 Hours of Le Mans as its headline event. Included for the first time will be Hypercars from Ferrari, Peugeot, Porsche and Toyota, which - together with models of all the cars of the 2023 full-season WEC entrants - will be competing on iconic tracks such as Spa-Francorchamps, Monza, Fuji and Circuit de la Sarthe.

09:10 EDT Riot Platforms produces 676 bitcoin in May - Reports average bitcoin produced per day 21.8. Reports bitcoin held 7,190. "In May, Riot successfully maintained steady and consistent production, mining 676 Bitcoin during the month," said Jason Les, CEO of Riot. "In addition, Riot also benefitted from participation in ERCOT's Demand Response programs, generating $2.4 million in revenue as a result of our unique power strategy, which is made possible by our long-term fixed rate power contracts. Riot's participation in these programs supports ERCOT's efforts to maintain grid reliability for the benefit of all Texans while also providing economic benefits to the Company."

09:08 EDT E-Home Household Service signs new contracts of over RMB 10M in April to May - E-Home Household Services announced E-Home Household Services Holdings Limited Service provider: YiJiaQin Jiangxi Branch of Household Services Group has been established. Meanwhile, eHome headquarters signed new contracts in April to May for Fuzhou Binhai Minshou Court, Fuzhou Binhai Shouqiju, Fuzhou Zhonglian Binjiang Building Community, Fuzhou Vanke Golden Garden, Shenzhen DTZ Fuzhou Industrial Bank, Fuzhou Poly Tang Yue Mansion, Fuzhou Sky City Marketing Center, Fuzhou Real Estate Office Building, Fuzhou Tianyue Phase II Marketing Center, Fujian Fuzhou Minhou Poly Read River Terrace, Yongtai Poly Tang Yue Marketing Center, Minhou Binjiang Project Phase I, Minhou Binjiang Project Phase II, Minhou Binjiang Project Phase III, Shimao ICT International and many other cleaning service projects with a combined amount of more than RMB 10 million.

09:06 EDT Lucy Scientific Discovery offers to acquire Pasithea for 85c per share - Lucy Scientific Discovery (LSDI) sent a proposal to Pasithea Therapeutics Corp. (KTTA), a biotechnology firm focused on innovative medical solutions, to acquire each share of its common stock. Under the terms of the offer, Lucy proposes to pay $0.60 in cash, and $0.25 cents in Lucy stock for every share of Pasithea common stock. Given that Pasithea's stock closed at $0.35 per share on June 1, 2023, the Proposal of $0.85 per share equates to 142% premium to Pasithea's share price. In fact, the cash component alone represents a 71% premium. Pasithea's most recent quarterly report indicates approximately $30,000,000 cash on hand. Given the significant market value discount to its net cash, Lucy believes its attractive offer will create immediate value from the cash portion with additional upside participation through Lucy's stock as it executes its business plan. In order to preserve cash for shareholders, Lucy intends to explore strategic alternatives for the divestiture of Pasithea's clinical development program. While Pasithea's 30-day average daily dollar trading volume is only $16,000, Lucy is an actively traded NASDAQ company with an average daily dollar trading volume of more than $1.8 million. This represents more than 100 times the dollar volume of Pasithea's trading and could substantially improve liquidity for its shareholders. In the event that the proposal is not endorsed by Pasithea's Board of Directors, Lucy is prepared to present it directly to the Pasithea shareholders.

09:04 EDT WWE announces multi-year partnership with Twitch - WWE announced a multi-year partnership with Twitch that will see the return of the official WWE channel and popular WWE Superstar channels, featuring live and exclusive content. In addition to the launch of the channel, WWE will debut today a companion sidecast to Monday Night RAW, bringing the WWE Universe behind the scenes and closer to the in-ring action. The weekly viewing experience will be led by a rotating cast of hosts and will regularly feature appearances by WWE Superstars, unique and exclusive content such as backstage interviews, and more. Viewers can stream the sidecast live every Monday beginning at 8 p.m. or the Twitch App. Additionally, the official WWE channel will be home to other live productions and will serve as an alternate live streaming feed for all of WWE's premium live event press conferences.

09:03 EDT GlobalFoundries, STMicroelectronics finalize deal for manufacturing facility - GlobalFoundries and STMicroelectronics announced the conclusion of the agreement to create a new, jointly-operated, high-volume semiconductor manufacturing facility in Crolles, which was announced on 11 July 2022. The program represents an overall projected cost of 7.5 billion euro for CAPEX, maintenance and ancillary costs. The new facility will benefit from significant financial support from the State of France. The aid measure, in line with the objectives set out in the European Chips Act and part of the "France 2030" plan, recently received approval from the European Commission.

09:01 EDT Optum submits proposal to combine with Amedisys for $100 per share - Optum, part of UnitedHealth (UNH), has submitted an all-cash proposal to the board of directors of Amedisys (AMED) to combine with Amedisys. The $100 per share all-cash transaction provides full and certain value to Amedisys shareholders. The proposed transaction represents a 26% premium over Amedisys' most recent closing share price and a premium of 29% to the unaffected Amedisys share price of $77.26. Optum's proposal has no financing contingency or condition and does not require shareholder approval.

08:56 EDT Biogen, Denali shift focus of Parkinson's Disease clinical development program - Biogen (BIIB) provided an update on its Parkinson's Disease clinical development program, stating in part: "As part of its ongoing Research & Development prioritization initiative and resource allocation, Biogen announced plans to revise the clinical development program for BIIB122, a small molecule inhibitor of leucine-rich repeat kinase 2, which is being developed in collaboration with Denali Therapeutics (DNLI). Prior to the planned revisions, the BIIB122 clinical development program encompassed two global late-stage clinical trials: the Phase 2b LUMA study in participants with early-stage Parkinson's disease, which commenced in May 2022; and the Phase 3 LIGHTHOUSE study in participants with Parkinson's disease related to LRRK2 mutations, which commenced in September 2022. In consideration of the LIGHTHOUSE study's complexity including the long timeline with anticipated study completion in 2031, Biogen and Denali have agreed that efforts will be refocused to enable a timely readout on efficacy in early-stage idiopathic Parkinson's disease while gaining further clinical data in Parkinson's disease with and without a LRRK2 mutation. The protocol for the LUMA study in patients with early-stage Parkinson's disease will be amended to now include eligible patients with a LRRK2 genetic mutation in addition to continuing to enroll eligible patients with early-stage idiopathic Parkinson's disease. The LIGHTHOUSE study of BIIB122 in patients with Parkinson's disease associated with LRRK2 mutations will be discontinued. Patients currently enrolled and randomized in LIGHTHOUSE will be offered the opportunity to join the LUMA study. These modifications are not based on any safety or efficacy data from studies of BIIB122. Denali and Biogen have a strategic collaboration to jointly develop and commercialize small molecule inhibitors of LRRK2 and remain committed to advancing the development of BIIB122." Reference Link

08:55 EDT Real Good Food launches low-carb, high protein burrito platfom - The Real Good Food Company announced the launch of their new cheesy burritos loaded with chunks of chicken breast and made with a proprietary low carb tortilla-available in the Club channel today, and coming to grocery stores in the coming months. Real Good Foods' burritos are made using chunks of antibiotic-free chicken breast and pepper jack and cheddar cheeses, seasoned with a hint of lime and cilantro and hand rolled into a proprietary low carb flour tortilla. These nutritious burritos extend Real Good Foods into a new category within Retail & Club, refrigerated Entrees. The Refrigerated Entrees category is a $4.1B category excluding Costco, and one of the fastest growing sub-categories in TTL US MULO, growing 10% vs. YAG and 22% vs. 2YAG L52 Weeks ending September 2022*.

08:55 EDT Pasithea Therapeutics Corp trading halted, news pending

08:54 EDT MamaMancini's launches series of On-the-Go products - MamaMancini's Holdings announced the launch of a new series of On-the-Go products at IDDBA 2023 to expand upon the initial success of its Meatballs in a Cup product line in convenience store trials. Expanding upon the MamaMancini's Beef Meatballs in Cup product, newly launched products include Turkey Meatballs in a Cup, Chicken Cacciatore in a Cup, Chana Masala in a Cup, Sausage, Peppers and Onions in a Cup, and Beef & Rice Stuffing in a Cup, all with a suggested retail price of $5.99. The product recipes are all-natural, preservative and soy free, and contain no artificial ingredients. Each cup comes fully cooked and microwave ready. New packaging has expanded the shelf life from 5 days to 21 days while retaining taste and texture - which helps to ensure quality, safety and reduced replenishment costs. The format and target consumer make it an attractive product for convenience stores, helping to drive incremental sales and larger basket sizes. The fact that convenience stores already have microwaves in-store further strengthens the business proposition.

08:52 EDT Research Frontiers appoints Eyal Peso to the board - Research Frontiers announced the appointment of Eyal Peso to the Research Frontiers Board of Directors effective June 4, 2023. Mr. Peso is the Co-Founder, Chairman of the Board of Directors and CEO of smart materials manufacturer Gauzy, Ltd.

08:50 EDT HF Foods Group says regains compliance with Nasdaq requirements - HF Foods Group announced that it held its Combined 2022-2023 Annual Meeting of Stockholders on June 1, 2023. The Annual Meeting was held to comply with the request/notification issued by the Listing Qualifications Department of Nasdaq on January 17, 2023. Following the completion of the Annual Meeting, the Company believes it has now regained compliance with all requirements for continued listing on the Nasdaq Capital Market.

08:49 EDT NRSInsights says May same-store sales increased 7.1% - NRSInsights announced comparative same-store sales results for May 2023. As of May 31, 2023, the NRS retail network comprised approximately 25,000 terminals scanning purchases at independent retailers including bodegas, convenience stores, liquor stores, grocers, and tobacco and sundries sellers nationwide, predominantly serving urban consumers. Retail Same-Store Sales Highlights: Same-store sales increased 7.1% from a year earlier. Sales increased 4.3% compared to the preceding month. The sequential increase is primarily attributable to May comprising 31 days compared to April's 30 days; Same-store sales in the preceding month had increased 6.5% compared to the year-ago month, and increased 0.1% compared to the preceding month despite April comprising 30 days compared to March's 31 days; For the three months ended May 31, 2023, same-store sales increased 6.4% compared to the three months ended May 31, 2022; The number of items sold during May 2023 increased 7.0% compared to May 2022 and increased 3.8% compared to April 2023; The average number of transactions per store in May 2023 increased 4.7% compared to May 2022 and increased 6.0% compared to April 2023;A dollar-weighted average of prices for the top 500 items purchased in May 2023 increased 3.2% year-over-year, an increase from the 3.1% year-over-year increase in April 2023.

08:48 EDT Cellebrite announces UFED Ultra solution - Cellebrite DI announced its new UFED Ultra solution which expands and accelerates data access, extraction, decoding, and review capabilities for law enforcement agencies around the world to deliver court-ready digital evidence. Cellebrite's UFED Ultra strengthens the end-to-end solution suite by broadening access to devices and operating systems thereby streamlining the investigative workflow and accelerating time-to-evidence. This technology and infrastructure provide unparalleled access and extraction capabilities meaning every agency with Cellebrite technology, regardless of size, is equipped to confidently solve more crimes faster.

08:46 EDT Janssen announces results from Phase 2 NORSE, Phase 2 RAGNAR studies - The Janssen Pharmaceutical Company announced the final results from its Phase 2 NORSE study and results from its Phase 2 RAGNAR Study. Final Results from Phase 2 NORSE Study Evaluating BALVERSA and Cetrelimab Combination Therapy: Presented were data from the Phase 2 NORSE study evaluating BALVERSA alone and in combination with cetrelimab, an investigational anti-programmed death receptor-1 monoclonal antibody, as first-line treatment of patients with mUC who were ineligible for cisplatin-based chemotherapy and who had FGFR alterations. Both the combination and monotherapy treatment demonstrated a clinically meaningful response, with an ORR of 54.5 percent in the combination arm and 44.2 percent in the monotherapy arm, and was well-tolerated in patients. In the combination arm, six patients achieved a complete response and one patient in the monotherapy arm achieved a complete response. Median PFS in the combination arm was 11.0 months, versus 5.6 months in the monotherapy arm. Grade three or higher TRAEs were observed in 45.5 percent of patients who received BALVERSA and cetrelimab combination therapy and 46.5 percent of patients who received BALVERSA monotherapy. Results from the Phase 2 RAGNAR Study Evaluating the Efficacy and Safety of BALVERSA: Additionally, data from the phase 2 RAGNAR study, evaluating the efficacy and safety of BALVERSA in patients with advanced or metastatic solid tumors with prespecified FGFR alterations, regardless of tumor location or histology, were also presented at ASCO this year. Treatment with BALVERSA demonstrated a clinically meaningful response at a median follow-up of 17.9 months, with an ORR of 30 percent. Responses were observed across 16 distinct tumors. Among the 64 responding patients, three percent of patients had a complete response and 27 percent of patients had a partial response. Grade three or higher TRAEs were observed in 46 percent of patients who received BALVERSA. Serious TRAEs were observed in 8.3 percent of patients and no deaths due to TRAEs were observed.

08:45 EDT Hill International awarded contract to provide project management support - Hill International was selected by the City of Phoenix Aviation Department to provide program management staff support services for the City of Phoenix's Capital Improvement Program, Terminal Modernization Program, Airport Development Plan, and Capital Management Division at Sky Harbor International Airport, Phoenix Deer Valley Airport, and Phoenix Goodyear Airport.

08:44 EDT Barnes Group: MB Aerospace to add $330M of revenue and $6M of EBITDA in FY23 - MB Aerospace is projected to generate approximately $330M of revenue and $6M of EBITDA in calendar year 2023. Barnes anticipates that the effective purchase price multiple will be approximately 11.4x 2023 EBITDA and 8.9x inclusive of pro forma estimated run rate cost synergies. Upon closing of the transaction, MB Aerospace will become part of Barnes Aerospace. Barnes expects to finance the transaction with cash on hand and additional acquisition financing. Upon closing, Barnes estimates net leverage to be between 3.7x and 3.9x Consolidated EBITDA, with a plan to reduce net leverage to below 3.0x within 12 months and 2.5x within 24 months following closing. "The acquisition of MB Aerospace, the largest in Barnes' history, is a transformational opportunity that is a significant catalyst for our already world class aerospace business. MB is an exceptional strategic fit for us with highly complementary program focus, global operations, technical capabilities, and product offerings. Like Barnes Aerospace, MB possesses a history and culture of operational and technical excellence through a skilled workforce, and global footprint that will help us drive productivity across the combined entity," said Thomas J. Hook, President and Chief Executive Officer of Barnes. "With manageable leverage, the realization of approximately $18 million in identified annual run-rate cost synergies, disciplined cash management, and a focus on core business execution, we anticipate solid returns on invested capital for this transaction. Coupled with Barnes' progressing multi-phase transformation initiative, we expect to deliver enhanced shareholder value," added

08:42 EDT CohBar, Morphogenesis announces results from Phase 1b trial of IFx-Hu2.0 - Morphogenesis and CohBar announced initial results from an exploratory analysis of anti-tumor responses to rechallenge with an ICI following protocol directed IFx-Hu2.0 therapy among patients with advanced MCC or cSCC who exhibited primary resistance to ICIs. The abstract titled, "Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma," was presented by Andrew Brohl, MD, H. Lee Moffitt Cancer Center and Research Institute in a poster presentation as part of the Melanoma/Skin Cancers - Advanced/Metastatic Diseases session held at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. IFx-Hu2.0 is Morphogenesis' lead personalized cancer vaccine candidate that is designed to overcome primary resistance to checkpoint inhibitors. In a Phase 1 study in advanced melanoma, biomarker analyses demonstrated robust immune priming effects of IFx administration. The ongoing Phase 1b study evaluates IFx-Hu2.0 in a two-stage study design to assess safety and to examine the effects of repeated weekly dosing up to 3 weeks on the magnitude of the ensuing systemic immune response to determine the optimal dose and schedule for the company's planned Phase 2/3 registration directed trial. As reported at ASCO, following completion of protocol directed therapy, 5 patients with advanced MCC and 2 patients with cSCC who, prior to study entry, failed anti-PD(L)1 therapy were re-treated with anti-PD(L)1 monotherapy: pembrolizumab or avelumab in MCC and cemiplimab in cSCC. Four of 5 patients with advanced MCC and 1 of 2 patients with cSCC, or 5 of 7 total, experienced objective anti-tumor responses to ICI rechallenge in this setting, with duration of response ongoing in 4 patients and one response lasting 23 months. All 4 patients with advanced MCC with post-protocol response to anti-PD(L1) therapy had previously experienced progression to this same drug class prior to treatment on protocol. Based on the positive preliminary results seen to-date, an additional 11 patients are planned for enrollment in the expansion stage of the Phase 1b study using the weekly x 3 dosing schedule. Additional exploratory/biomarker analyses are planned.

08:41 EDT Enlight Renewable to supply renewable energy to Amdocs - Enlight Renewable Energy (ENLT) has entered into a corporate power purchase agreement with Amdocs (DOX). Under the agreement, Enlight will supply green energy to Amdocs to power the software giant's new office campus in Israel. The PPA, which extends for 12 years, is expected to account for 100% of the energy consumption at Amdocs' new innovative campus "Amdocs Park," which spans dozens of acres. The electricity, which will be sold at a competitive price, will be sourced from Enlight's solar and storage facilities currently under construction in Israel. The agreement marks the first corporate PPA Enlight has signed as part of the new market regulation in Israel.

08:40 EDT National CineMedia enters affiliate transaction agreement with Regal Cinemas - National CineMedia announced that it has entered into a new long-term network affiliate transaction agreement with Regal Cinemas. Through the agreement, NCM acquires the exclusive right to provide on-screen advertisements at Regal Cinemas' over 6,000 screens and 450 theaters. NCM will run its industry leading Noovie show, featuring hundreds of national, regional, and local advertisers, as well as the high impact Platinum ad unit within the trailers, on Regal Cinemas' screens across the United States. The Agreement is subject to approval by the United States Bankruptcy Court for the Southern District of Texas, which is expected to occur on or before June 30, 2023. This Agreement represents a major milestone in the NCM's restructuring and culminates its successful mediation with Regal Cinemas.

08:40 EDT Neximmune presents data from NEXI-001 Phase 1 trial - NexImmune announced results from its Phase 1/2 clinical trial of NEXI-001 in patients with relapsed/refractory acute myeloid leukemia post-allogeneic hemopoietic stem cell transplant. In this clinical trial to date, NEXI-001 is well tolerated with a favorable safety profile while eliciting an immune response to target antigens and a clinical effect in some patients. The data describing two patients from the dose escalation study of NEXI-001 are being presented in a poster session at the American Society of Clinical Oncology 2023 Annual Meeting in Chicago on Monday, June 5 at 8 AM in Hall A. The goals of the NEXI-001 Phase 1 clinical trial are to evaluate the safety, tolerability, immune response, and clinical activity of the antigen-specific CD8+ NEXI-001 T cells, as well as to inform the range of patient characteristics and to determine the recommended Phase 2 dose. The dose escalation phase of the study included patients who have relapsed acute myeloid leukemia post allo-HSCT and are refractory to salvage therapy. All patients in the study, except one, relapsed after, or were refractory to, subsequent salvage therapies. A majority of patients had three-to-four adverse risk characteristics linked to poor prognosis in addition to poor prognostic patients with extramedullary disease. Three dose-ascending cohorts of patients were enrolled in the study, with potential doses ranging from a single dose of 50 million NEXI-001 T cells to multiple doses of up to a total of 1.2 billion NEXI-001 T cells. To date, the maximum dose evaluated has been 600 million NEXI-001 T cells. The study includes a lymphodepletion chemotherapy following a baseline bone marrow biopsy. To date, 11 patients have completed the dose-limiting toxicity period and one patient is currently ongoing in the first month of protocol treatment. Through all dose levels to date, NEXI-001 maintains a favorable tolerability profile with no grade 3 or greater treatment related SAEs. Two patients experienced grade 2 CRS which resolved within 24 hours with tocilizumab therapy. No cases of ICANS have occurred as of May 2023. Patients treated with NEXI-001 experienced rapid reconstitution of both CD8+ and CD4+ T-cell subtypes after lymphodepletion chemotherapy. Clinicians observed persistence of antigen-specific T cells in both peripheral blood and bone marrow with evidence of clinical activity including tumor burden reduction, increased chimerism and improved ECOG scores. The antigen-specific T cells maintain less-differentiated immunophenotypes, including stem-cell-like T cells over time in both blood and bone marrow. Additionally, a marked increase in the antigen specificity of CD8+ T cells in the bone marrow resulted with increasing dose levels. Six of 11 patients across all dose levels experienced stable disease for some period, including a stable clinical response in one patient and one CR for up to 9 months in cohort 2 which was reported in the ASCO poster. Data continue to support potential dose response with 600 million total cells infused during Cycle 1 being the maximum dose evaluated as of May 2023. Additional cycles or dose increases are anticipated to offer benefit in the designed expansion phase of the study. One patient in Cohort 3 with a poor prognostic extramedullary relapse of AML manifested by pericardial and bilateral pleural effusions resulting in symptoms of moderate to severe dyspnea was enrolled in the highest dosing cohort. After one cycle of protocol therapy the patient became asymptomatic and repeat PET/CT scans document that the effusions regressed to minimal volumes. This extramedullary clinical response has been maintained for up to 7 months and is updated from the 3 months described in the ASCO poster. These data indicating both immunologic and clinical dose responses and observed durability in the patient at the higher dose support further clinical study of NEXI-001.

08:39 EDT Amyris initiates strategic transformation program, secures funding - Amyris announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers and established a subcommittee of the Board, made up of three independent directors, working with Management, to execute on a transformation program to accelerate improvements to the Company's cost and capital structure and liquidity. John Melo, Chief Executive Officer and President, commented, "We are pleased with the support of the PwC team as well as our board Restructuring Committee on the expansion and acceleration of our "Fit to Win" efficiency and cost reduction program. It is an important and necessary step in the evolution of Amyris to reduce our cost base, improve our operational effectiveness and achieve sustainable growth while continuing to execute the delivery of sustainable chemistry through our Lab to MarketTM capabilities and invest in our leading consumer brand portfolio. We are executing our strategy and accelerating our path to profitability."

08:37 EDT Sun Life appoints Garg as SVP, Corporate Development, Investor Relations - Sun Life Financial announced the appointment of David Garg as Sun Life's Senior Vice-President, SVP, Corporate Development and Investor Relations. David joined Sun Life in November 2021 as Senior Vice-President of Corporate Development, and since that time has led mergers, acquisitions and strategic investments across the company. In this expanded role, David will be responsible for developing Sun Life's investor communications and managing relationships with institutional investors, sell-side analysts and rating agencies. Yaniv Bitton, who is currently Vice-President, Head of Investor Relations & Capital Markets, will take on a new role as Vice-President and CFO, Retail Advice & Solutions for Sun Life Canada.

08:36 EDT Servotronics announces Star Equity withdrew its two board nominees - Servotronics (SVT) announced that on June 1, 2023 Star Equity Fund, L.P. notified the Company that Star Equity (STRR) was withdrawing its two nominees for election to the Company's Board of Directors. The withdrawal of Star Equity's nominees is not the result of any concessions by the Company nor a negotiated settlement with Star Equity. Due to the limited time between Star Equity's withdrawal of its nominees and the June 9, 2023 Annual Meeting, Servotronics is not able to provide shareholders a revised proxy card that does not include the withdrawn nominees. Shareholders who wish to vote on the election of directors and other proposals to be considered at the Annual Meeting should vote on the Company's BLUE proxy card or voting instruction form.

08:36 EDT CPI Card Group says CEO Scott Scheirman intends to retire February 28 - CPI Card Group announced that Scott Scheirman has informed the Board of Directors of his intention to retire as President and Chief Executive Officer. Scheirman will continue to serve as President and Chief Executive Officer until a successor is named and intends to retire from the Company effective February 28, 2024 providing ample time for the selection of a successor and a smooth transition of leadership. CPI's Board of Directors has a succession plan in place to identify and evaluate candidates and expects to name a new CEO in late 2023 or early 2024. In retirement, Scheirman plans to spend more time with his family and return to volunteer work with community organizations focused on helping kids.

08:34 EDT Bristow Group releases second Sustainability Report - Bristow Group released its second Sustainability Report, expanding upon the achievements outlined in last year's inaugural report, further demonstrating the Company's commitment to responsible growth and environmental stewardship, highlighting its role as a sustainability leader within the vertical lift industry. "Sustainability means striking the right balance between our economic, social, and environmental responsibilities," said Bristow President and CEO, Chris Bradshaw. "We must strive to have as limited an impact on our local environments as possible. We must also ensure our operations remain robust through the contributions of a diverse and engaged workforce, providing the safe and exemplary service customers have come to expect from us over the past 75 years. This report demonstrates our forward progress on this journey."

08:33 EDT CERo Therapeutics to become public through Phoenix Biotech Acquisition pact - CERo Therapeutics and Phoenix Biotech Acquisition (PBAX), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, anticipated to occur in the second half of 2023, the combined company will be named CERo Therapeutics Holdings and will be led by CERo and PBAX's founding members, including Daniel Corey, CERo's CEO, Chris Ehrlich, PBAX's CEO, and Brian G. Atwood, the chairman of PBAX. The combined company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol (CERO). Atwood will serve as CEO of the combined company, Ehrlich will serve as its CFO and COO and Corey will serve as its CTO. The resources of the combined company are expected to provide CERo with the capital to advance CER-1236, its lead product candidate, into clinical trials for hematologic malignancies and expand the clinical development of CER-1236 into other difficult to treat cancers, including solid tumors. Upon the closing of the business combination, and assuming no redemptions of shares of PBAX by its public stockholders, CERo would expect to receive up to $13.7M of cash held in trust. The business combination reflects a pre-money equity value of $50M for CERo and a pro forma capitalization of the combined company of $145M. The business combination is subject to a minimum cash condition of $30M, net of transaction expenses, which is expected to be funded through proceeds of the trust account and additional financing, including investments from existing stockholders of CERo. The parties intend to seek to secure such additional financing through a private placement. The boards of directors of both CERo and PBAX have unanimously approved the proposed transaction with expected completion in the second half of 2023. The closing of the transaction is subject to approval of PBAX shareholders and the satisfaction, or waiver of, the minimum cash condition and certain other customary closing conditions.

08:32 EDT AstraZeneca announces updates results from TROPION-Lung02 Phase Ib trial - Updated results from the TROPION-Lung02 Phase Ib trial showed that, with additional enrolment and follow-up from the initial presentation, datopotamab deruxtecan in combination with pembrolizumab with or without platinum-based chemotherapy demonstrated promising clinical activity and no new safety signals in both previously untreated or pretreated patients with advanced or metastatic non-small cell lung cancer, NSCLC, without actionable genomic alterations. Results will be presented on 6 June in an oral presentation at the 2023 American Society of Clinical Oncology, ASCO. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate being jointly developed by AstraZeneca (AZN) and Daiichi Sankyo (DSNKY). Across previously untreated and pretreated patients, an objective response rate, ORR, of 38% was observed in patients receiving doublet datopotamab deruxtecan plus pembrolizumab, an anti-PD-1 therapy. In patients receiving triplet datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy, an ORR of 49% was observed. Disease control rates, DCR, of 84% and 87% were observed in the doublet and triplet cohorts, respectively. Median duration of response was not reached across cohorts. Although immature, median progression-free survival was 8.3 months in the doublet cohort and 7.8 months in the triplet cohort. Response rates were highest in previously untreated patients with ORRs of 50% and 57% observed in the doublet and triplet cohorts, respectively, with a consistent DCR of 91% observed across cohorts. The safety profiles of datopotamab deruxtecan-based combinations were consistent with previous data with no new safety signals observed. Grade 3 or greater treatment-related adverse events occurred in 31% of patients receiving doublet therapy and 58% of patients receiving triplet therapy. The most frequent adverse events of any Grade in the doublet and triplet cohorts, respectively, were stomatitis, nausea, anaemia and fatigue. Eighty percent of patients in the doublet cohort and 73% of patients in the triplet cohort had PD-L1 tumour proportion scores of less than 50%, including 36% and 40% of patients who had PD-L1 tumour proportion scores of less than 1% in the doublet and triplet cohorts, respectively. As of the April 7, 2023 data cut-off, 36% and 46% of patients remained on the doublet and triplet therapy, respectively.

08:30 EDT Electromed appoints Jim Cunniff as new President and CEO - Electromed announced the appointment of Jim Cunniff as its new President and Chief Executive Officer effective July 1. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams.

08:27 EDT Taysha Gene Therapies announces first patient dosed with TSHA-102 - Taysha Gene Therapies announced that the first patient has been dosed with TSHA-102 in the Phase 1/2 REVEAL trial evaluating the safety and preliminary efficacy of TSHA-102 in adult patients with Rett syndrome. TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element platform designed to regulate cellular MECP2 expression. The study is being conducted at CHU Sainte-Justine, the Universite de Montreal mother and child university hospital centre in Montreal, Canada. The Phase 1/2 REVEAL trial is a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in adult females with Rett syndrome due to MECP2 loss-of-function mutation. Participants will receive a single lumbar intrathecal injection of TSHA-102. Dose escalation will evaluate two dose levels of TSHA-102 sequentially, with an initial dose of 5x1014 total vector genomes and the second dose of 1x1015 vg. The maximum tolerated dose or maximum administered dose established will then be administered during dose expansion. Per the protocol, an independent data monitoring committee will review available safety data from the first patient at approximately six weeks post-dosing to determine if the Company can proceed with dosing the second patient. Initial available clinical safety data will be reported at Taysha's upcoming R&D Day on June 28, 2023

08:26 EDT Immuneering completes dose escalation in IMM-1-104 Phase 1 trial - Immuneering Corporation announced the completion of the dose-escalation portion of the Phase 1/2a study for its lead asset IMM-1-104 in patients with advanced solid tumors. The study's Safety Review Committee completed its evaluation and determined that doses up to and including 320 mg once daily are tolerable with no dose limiting toxicities. Enrollment in the Phase 1b expansion portion of the study will now commence and is designed to evaluate two dosing cohorts of 12 patients each at an oral dose of 240mg or 320 mg once daily. Three patients already enrolled in the study have been dosed at the 320 mg dose level. In April 2023, Immuneering presented initial Phase 1 PK, PD and safety data for IMM-1-104 at the American Association for Cancer Research annual meeting. IMM-1-104 achieved significant levels of PK Cmax, demonstrated a half-life of approximately two hours, as predicted, and was well tolerated with no dose limiting toxicities. Upon review of the cumulative data from the eight patients dosed in the Phase 1a study, the SRC endorsed 240 mg daily and 320 mg daily as the dose levels for the expansion cohort and agreed with initiating the Phase 1b expansion.

08:23 EDT A-Mark Precious Metals increases share repurchase program up to 1M shares - The board of directors of A-Mark Precious Metals has authorized an increase in the number of shares which may be repurchased under the Company's existing share repurchase program and extended the expiration date of the program from June 30, 2023 to June 30, 2028. Under the revised program, A-Mark is authorized to repurchase up to 1,000,000 shares of its outstanding common stock, in addition to the 335,735 shares repurchased under the program as of March 31, 2023.

08:23 EDT AstraZeneca says Enhertu showed ORR of 37.1% in DESTINY-PanTumor02 Phase 2 trial - "Positive" results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that Enhertu demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients, AstraZeneca announced. These results will be presented today as a late-breaking oral presentation at the 2023 American Society of Clinical Oncology, or ASCO, Annual Meeting. In the trial, previously treated patients with HER2-expressing advanced solid tumors including either biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers or other tumors treated with Enhertu showed a confirmed objective response rate, or ORR, of 37.1%, as assessed by investigator at an interim analysis. A greater response was observed in patients with the highest level of HER2 expression, where Enhertu demonstrated a confirmed ORR of 61.3% as confirmed by central testing. A complete response, or CR, was observed in 15, or 5.6%, patients in the overall trial population, with 84, or 31.5%, partial responses observed, and 123, or 46.1%, patients achieving stable disease. The disease control rate, or DCR, in the overall trial population was 68.2%, as assessed by investigator.

08:20 EDT Rani Therapeutics, Celltrion expand partnership for RT-105 - Rani Therapeutics Holdings announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar. Rani's first partnership with Celltrion, for the development of RT-111, an orally administered ustekinumab biosimilar, was announced in January of this year. Under the terms of the new license and supply agreement, Celltrion will exclusively supply to Rani the adalimumab biosimilar drug substance required for RT-105. Rani is granted an exclusive license to use CT-P17 in the development and commercialization of RT-105, and Celltrion is granted a right of first negotiation to acquire worldwide rights to RT-105 following a Phase 1 study.

08:18 EDT Apollo Funds to invest $2B in preferred equity of AT&T Mobility II - Apollo (APO) has agreed to invest $2B in preferred equity securities to be issued by AT&T Mobility II LLC, a subsidiary of AT&T (T). AT&T Mobility II LLC will use the proceeds from the investment to partially replace the $8B of preferred interests that were outstanding prior to the fourth quarter of 2022. The investment, expected to be completed in June 2023, allows Apollo's insurance and institutional clients to access investment-grade rated securities in one of the nation's leading wireless businesses.

08:17 EDT AstraZeneca reports interim analysis from DESTINY-PanTumor02 trial - Results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that Enhertu demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients. These results will be presented as a late-breaking oral presentation at the 2023 American Society of Clinical Oncology, or ASCO, annual meeting. Enhertu is a specifically engineered HER2-directed antibody drug conjugate, or ADC, being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. In the trial, previously treated patients with HER2-expressing advanced solid tumors including either biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers or other tumors treated with Enhertu showed a confirmed objective response rate, or ORR, of 37.1%, as assessed by investigator at an interim analysis. A greater response was observed in patients with the highest level of HER2 expression immunohistochemistry, where Enhertu demonstrated a confirmed ORR of 61.3% as confirmed by central testing. A complete response, or CR, was observed in 15 patients in the overall trial population, with 84 partial responses observed, and 123 patients achieving stable disease. The disease control rate in the overall trial population was 68.2%, as assessed by investigator. Nearly half of all patients in DESTINY-PanTumor02 who achieved a response remained in response at one year. Median duration of response was 11.8 months in the overall trial population and 22.1 months in patients with IHC 3+ expression. The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified. The most common Grade 3 or higher treatment-related treatment-emergent adverse events were neutropenia, anemia, fatigue and thrombocytopenia. In DESTINY-PanTumor02, 20 patients experienced interstitial lung disease or pneumonitis related to treatment with Enhertu as determined by an independent adjudication committee. The majority were low Grade with one Grade 3 event, no Grade 4 events and one Grade 5 event observed. DESTINY-CRC02 primary results support 5.4mg/kg as optimal dose of ENHERTU in patients with HER2-positive metastatic colorectal cancer. Primary results from the DESTINY-CRC02 Phase II trial, which evaluated Enhertu at the 5.4mg/kg and 6.4mg/kg doses in patients with previously treated locally advanced, unresectable or metastatic HER2-positive colorectal cancer of BRAF wild-type, RAS wild-type or RAS mutant tumor types, were also presented at ASCO. In the primary endpoint analysis, a confirmed ORR of 37.8% and 27.5% was seen in patients in the 5.4mg/kg and 6.4mg/kg arms respectively, as assessed by blinded independent central review. All responses were partial, with 40 patients in the 5.4mg/kg arm and 23 patients in the 6.4mg/kg arm achieving stable disease. Greater efficacy was observed in patients with the highest levels of HER2 expression compared to those with IHC 2+/ISH+ HER2 status in the 5.4mg/kg treatment arm. Anti-tumor efficacy was observed regardless of RAS mutation status and in those with prior HER2-directed therapy in the 5.4mg/kg arm. Enhertu also demonstrated a median DoR of 5.5 months in both the 5.4mg/kg and 6.4mg/kg arms with a median duration of follow-up of 8.9 months and 10.3 months in the two arms respectively. Median progression-free survival was 5.8 months in the 5.4mg/kg arm and 5.5 months in the 6.4mg/kg arm. Median overall survival was 13.4 months in the 5.4mg/kg arm and not reached in the 6.4mg/kg arm. The safety profile observed in DESTINY-CRC02 at the 5.4mg/kg and 6.4mg/kg dose levels was consistent with other clinical trials of Enhertu, with no new safety signals identified at either dose. A more favorable benefit-risk profile was observed in patients treated with Enhertu 5.4mg/kg, resulting in its selection as the recommended dose. Grade 3 or higher treatment related TEAEs were numerically higher with Enhertu 6.4mg/kg versus 5.4mg/kg. Grade 3 or higher treatment related TEAEs occurred in 41.0% and 48.7% of patients receiving ENHERTU 5.4mg/kg or 6.4mg/kg, respectively. The most common Grade 3 or higher TEAEs occurring in greater than 10% of patients were neutropenia, anemia, 23.1% and thrombocytopenia; 12.8%. There were 12 cases of treatment related ILD or pneumonitis reported, as determined by an independent adjudication committee. The majority were low Grade with no Grade 3, no Grade 4 and one Grade 5 event observed.

08:17 EDT Osisko Gold publishes 2023 Asset Handbook - Osisko has built a deep portfolio of high-quality royalty and streaming assets, located in favourable jurisdictions and operated by responsible mining partners. The royalty and stream portfolio provides exposure to over 180 assets, including over 20 producing assets which underpin Osisko's 2023 guidance of 95,000 to 105,000 gold equivalent ounces at a 93% cash margin2. To this solid foundation, significant organic growth is expected over the coming years, demonstrated by the Corporation's previously announced five-year outlook which projects 130,000 to 140,000 GEOs in 2027. Osisko's mining partners continue to add value through exploration, with an average of over 1 million meters drilled over the past six years. This ongoing work has unlocked significant upside through new discoveries, reserve and resource additions, as well as mine life extensions and expansions. Over the course of 2022, Osisko's estimate of Attributable GEOs3 in the proven and probable reserve category, net of depletion and covered by Osisko's royalties and streams, increased by 46%; demonstrating the importance of these shared assets to both Osisko and its operating partners.

08:16 EDT Ryvyl announces board approval of coyni merger - RYVYL announced the Board of Directors has approved the merger of coyni Inc., RYVYL's wholly owned subsidiary, and Logicquest Technology, Inc a shell company majority owned by RYVYL. Upon completion of the merger, Logicquest will amend its Articles of Incorporation to change its name to coyni, Inc. and request a symbol change with FINRA. Effectuation of the merger and symbol change are subject to any comment from FINRA on its company-related action.

08:16 EDT Nokia selected by Charter to support 5G connectivity - Nokia (NOK) announced that Charter Communications (CHTR) is turning to Nokia's comprehensive AirScale equipment portfolio, including 5G RAN, to support its targeted 5G connectivity design and deployment. A leading broadband connectivity company, Charter will use Nokia's 5G RAN solutions to deliver wireless 5G connectivity, faster speeds, and increased network capacity to Spectrum Mobile customers in its trial markets in the United States. This is the first win for Nokia in the Multiple System Operator space.

08:15 EDT Stagwell Instrument launches content innovation, experience innovation services - Stagwell's Instrument - a multidisciplinary creative company that redefines brands and experiences - announced the launch of two new core service offerings: content innovation and experience innovation, led by Paul Welch and Mike Creighton, executive directors at Instrument, respectively. These units will work with existing and prospective clients to unleash innovation at scale across partners' content, digital experiences, and technology infrastructure. "Brands are ecosystems which interact with people millions of times every day: emerging technology reveals new opportunities for brands to engage with consumers by creating new experiences on nascent channels, media, and capabilities," said Mike Creighton. "AI, web3, the metaverse, gaming, XR - they all represent potential opportunities. To navigate them and find what's right for our clients, we avoid riding hype cycles."

08:13 EDT Enveric Biosciences gets NOA from USPTO pertaining to its EVM301 compounds - Enveric Biosciences announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders. The soon-to-issue patent titled, "Carboxylated Psilocybin Derivatives and Methods of Using" contains composition of matter claims for a family of tryptamine-based drug candidates. Enveric is progressing its EVM301 Series of compounds through lead generation and candidate characterization efforts as it aims to develop compounds that engage the serotonin 5HT2a receptor and other neurotransmitter receptors to promote neuroplasticity and, consequently, therapeutic benefit without inducing the hallmark hallucinations associated with most psychedelic and psychedelic-inspired molecules. This innovative therapeutic approach could be game-changing in the treatment of depression and anxiety disorders by offering the opportunity to administer medications without requiring a healthcare professional to be present during treatment. Enveric believes this paradigm would significantly enhance the commercial potential for its EVM301 Series drug candidates when compared to the market for currently anticipated treatment modalities for first-generation psychedelics undergoing late-stage clinical studies. "Our EVM301 Series of molecules are designed based on tryptamines, long established as potent binders of the targeted 5HT2a receptor," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "The potential to capture composition-of-matter patent claims in the tryptamine field is challenging for most entrants as the creation of novel tryptamines has been an area of concentrated scientific focus for decades. Those tryptamines currently undergoing the most widespread clinical studies, such as psilocybin, DMT and 5MeO-DMT, are also challenging to protect because they are derived from natural sources. Naturally occurring molecules are not patentable, per se, as compositions of matter, but instead require non-obvious innovations in synthesis, formulation, or method of use, to secure patents. The narrower scope inherent to these types of patents can be less effective in protecting products from marketplace competitors."

08:13 EDT Replimune Group appoints Veleka Peeples-Dyer to board of direcots - Replimune Group announced the appointment of Veleka Peeples-Dyer to the Company's Board of Directors effective June 1, 2023. Ms. Peeples-Dyer has served as a strategic enterprise leader at leading biopharmaceutical companies serving as in-house counsel for over 16 years.

08:11 EDT WiMi Hologram Cloud launches WiMi AI Assistant - WiMi Hologram Cloud launched an artificial intelligence assistant using an advanced transformer algorithm, called WiMi AI Assistant, which is built up through years of R&D and improvement. WiMi successfully applied the transformer algorithm to natural language processing, providing users with a more intelligent and efficient communication platform. WiMi Hologram Cloud has always been committed to the R&D and application of innovative technologies. The launch of the WiMi AI Assistant is another significant breakthrough in artificial intelligence. WiMi will continue to increase its investment in R&D to provide users with more high-quality intelligent products and services.

08:09 EDT Mind Medicine: ISS recommends shareholders vote for all MindMed's nominees - Mind Medicine announced that leading proxy advisory firm Institutional Shareholder Services has recommended shareholders vote for ALL of MindMed's six highly qualified director nominees at the upcoming Annual Meeting of Shareholders scheduled for June 15. In its report supporting MindMed's nominees, ISS notes the following: "The company's regulatory strategy appears reasonable and has received third-party validation, and the drop in the company's share price after its September 2022 equity raise is in line with sectoral trends." "The board has also undergone a complete refresh of its ranks, yielding a strong cohort of independent directors, all with industry experience. Against this backdrop, the dissident has not made the case for change at MindMed." "As the dissident has not presented a convincing case for change at the company, support for all management nominees is warranted." ISS highlights the Company's Board refreshment, the relevant experience of MindMed's candidates and the Board's positive corporate governance: "The board's full refreshment of all six members began on Sept. 29, 2021, with the appointment of Vallone and Krebs, and the company expects to complete the refreshment at this year's AGM with the election of its new nominee, Gryska." "In this process, the board has been able to attract an unusually strong collection of former and current executives in the fields of mental health drug development and commercialization and financial management ." "The board utilizes many conventional governance best practices, such as an independent chair, annual director elections, a well-refreshed board, and a majority voting standard for director elections with a director resignation policy."

08:08 EDT DZS, Irby Utilities announces deployment milestones by customers - DZS and its strategic partner Irby Utilities announced deployment milestones reached by two of their rural electric cooperative broadband customers. Connect2First, a subsidiary of First Electric Cooperative in central and southeastern Arkansas, and FASTnet, an Internet Service Provider (ISP) launched by 4-County Electric Power Association in central Mississippi. Each have deployed hyper-fast broadband to over 12,000 subscribers to date, more than doubling their respective homes passed over the last year. Both service providers are leveraging Irby's broadband network planning and deployment expertise along with multi-gigabit capable DZS technology solutions and a total of more than $50 million in Rural Digital Opportunity Funds plus other government funding programs like the Coronavirus Aid, Relief, and Economic SecurityAct, to ultimately bring services to more than 140,000 homes, businesses and anchor institutions between their two service areas. Each project currently stands well ahead of schedule.

08:06 EDT Timber Pharmaceuticals announce FDA grant of CARC waiver for TMB-001 - Timber Pharmaceuticals announced the U.S. Food and Drug Administration has granted a dermal carcinogenicity waiver for TMB-001, a topical isotretinoin formulated using the Company's patented IPEG delivery system. The positive opinion is based on results of a 39-week repeat dose dermal toxicity study that demonstrated no evidence of skin or organ carcinogenicity from chronic applications of TMB-001 in rodents and allows the Company to forgo a 2-year dermal rodent carcinogenicity study. CI is a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin. TMB-001 is currently being investigated in the Phase 3 ASCEND study for the treatment of moderate to severe subtypes of CI including lamellar ichthyosis and X-linked ichthyosis that affect about 80,000 people in the U.S. In 2018, the FDA awarded an Orphan Products Grant to support clinical trials evaluating TMB-001, including the Phase 3 ASCEND study. Timber has also received both Breakthrough Therapy Designation and Fast Track Status from the FDA for TMB-001.

08:05 EDT Masimo receives FDA clearance for Radius VSM - Masimo announced that Radius VSM, a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510 clearance. Designed on a modular platform, Radius VSM allows clinicians to monitor a wide variety of physiological measurements, including Masimo SET pulse oximetry, noninvasive blood pressure, temperature, respiration rate, and electrocardiography. By combining the reliability and accuracy of larger bedside monitors with the comfort and freedom of a wearable device, Radius VSM allows ambulation and movement while ensuring patients remain continuously monitored. With its flexibility and expandability, Radius VSM can be easily scaled to match each patient's unique monitoring needs and level of acuity, across the continuum of care, and to accommodate surges in patient volume.

08:04 EDT SpartanNash names Brandon Pasch as VP, Center Store Merchandising - Food solutions company SpartanNash announced the hiring of Brandon Pasch as Vice President, VP, Center Store Merchandising, effective immediately. Pasch will play a key role in advancing the Company's merchandising transformation, developing strategy and driving winning results in a major segment of SpartanNash's business. Pasch joins the team following the recent hire of Arpen Shah as Vice President, Merchandising Strategy and Analytics, last month. Pasch most recently served as Vice President of Merchandising, Center Store at Giant Eagle, a supermarket chain with more than 400 retail locations.

08:00 EDT Fairfax Financial partners with Kennedy Wilson to acquire loan portfolio - Fairfax Financial Holdings (FRFHF) announce that it has agreed with Kennedy-Wilson Holdings, Inc. (KW) that, through certain of its subsidiaries, it will acquire an interest of approximately 95% in certain of the real estate construction loans that Kennedy Wilson has agreed to acquire from Pacific Western Bank, a bank holding company headquartered in California. The total purchase price for the Loans is approximately $2.1 billion, of which Fairfax will fund 95%. The aggregate principal balance currently outstanding under the Loans is approximately $2.3 billion. Fairfax will also assume approximately 95% of all future funding obligations under the Loans, subject to customary conditions to disbursement, which future funding obligations attributable to Fairfax total approximately $1.7 billion. The aggregate principal balance of the Loans, which are floating rate, currently carries an average interest rate of approximately 8.6%, and Fairfax has entered into interest rate swap arrangements to effectively fix this rate over the life of the Loans. The weighted-average remaining term to maturity for the Loans based on gross commitments is approximately 1.7 years, with some Loans subject to customary extension rights by the borrower up to a maximum of two additional one-year terms. Taking into account the discount at which Fairfax acquired the principal balances of the Loans, Fairfax expects the average annual return on the capital deployed by Fairfax in connection with the Loans to exceed 10%. All of the Loans are secured by real property located in the United States with an average loan-to-value ratio of approximately 51% and are supported by completion guarantees issued by the project equity sponsors. More than 70% of the Loans relate to multifamily or student housing development projects with the balance being a mix of industrial, hotel and life science office property development projects. The closing of the Transaction and the sale of each Loan is subject to the satisfaction of customary closing conditions, and it currently expected to close in multiple tranches during the second and early part of the third quarter of 2023. If a required counterparty consent or waiver in respect of a single Loan is not obtained, Fairfax will not be obligated to acquire that Loan but Fairfax's rights and obligations with respect to the acquisition of each other Loan will be unaffected. In addition to the Transaction, Fairfax also agreed to make a $200 million preferred equity investment in Kennedy Wilson. Under the terms of the agreement relating to the investment, Fairfax will acquire perpetual preferred stock that carries a 6.0% annual dividend rate and is callable by Kennedy Wilson at any time. Additionally, Fairfax acquired 7-year warrants for approximately 12.3 million common shares with an initial strike price of $16.21 per share, based on Kennedy Wilson's closing price on June 2, 2023. The investment is subject to customary closing conditions and is expected to close during the second quarter of 2023.

07:50 EDT Entegris terminates distribution pact with Element Solutions unit for $200M - Entegris (ENTG) announced that it has terminated its distribution agreement with MacDermid Alpha Electronics Solutions, a business unit of Element Solutions (ESI), in exchange for $200M. Entegris has received $170M at closing and the remainder will be paid at the conclusion of a transitionary period. This distribution agreement, originally entered into in 2003, provided Entegris the exclusive right to distribute MacDermid Enthone ViaForm copper plating chemistries, which are used in front-end chip making electrochemical deposition processes. Entegris is committed to ensuring a smooth customer transition process in connection with this transaction. Entegris expects that the proceeds of this transaction will contribute to further debt paydown. In 2022, the ViaForm product had sales of approximately $55M. Element Solutions is the manufacturer of the ViaForm product line, which Entegris has sold under a distribution agreement as a part of Entegris' Specialty Chemicals and Engineered Materials division product offerings. This transaction is consistent with Entegris' focus on assets that the company believes have the greatest long-term strategic value for Entegris and best positions it to serve its customers with advanced materials for the leading-edge technology nodes. This transaction does not include any other surface preparation and integration products or other product lines within SCEM division.

07:45 EDT Element Solutions announces two semiconductor transactions - Element Solutions announced two transactions that represent approximately $15M of annualized adjusted EBITDA with significant growth potential as electronics markets improve and certain new technologies win customer qualifications. Element Solutions has agreed to pay $185M, net of estimated cash tax benefits, to Entegris to terminate its long-standing distribution agreement for ViaForm electrochemical deposition products. These wafer level plating products for the world's largest semiconductor fabricators are currently developed and manufactured by MacDermid Alpha Electronics Solutions, a business unit of Element Solutions, and have been distributed by Entegris under an evergreen distribution agreement. Following a transition period, Element Solutions will manage all aspects of the ViaForm product line in-house, which we believe will result in a more efficient supply chain and improved customer outcomes. The payment will be funded by a combination of cash on hand and an incremental $150M borrowing under the company's senior credit facility. Element Solutions has acquired Kuprion, a developer of next-generation nano-copper technology to the semiconductor, circuit board and electronics assembly markets. The company's ActiveCopper technology addresses the effects of thermal expansion and offers superior performance and reliability in a host of growth applications, including electric vehicles, high frequency 5G networks, IC substrate manufacturing, advanced packaging, mission critical aerospace and defense systems, and datacenters. This transaction has been structured with an upfront payment and potential earn-out payments based on milestones associated with product qualification and revenue over several years.

07:42 EDT Western Alaska Minerals commences 2023 Field Season - Western Alaska Minerals announced commencement of operations and exploration activities at its 100% owned Illinois Creek Mining District. The Company continues to make significant progress in advancing its high-grade, district-scale mineral system, positioning itself for continued exploration success. Highlights: Drilling began on June 2, 2023: Objective #1: In-fill drilling at the Waterpump Creek Prospect proximal to the 2022 major intercept to support estimating an inferred mineral resource; Objective #2: Step-out drilling to expand on the 2022 drilling success of consecutive thick, ultra high-grade intercepts at WPC and to test new promising targets; 113 Km of line cutting have been completed in preparation for the Dias Geophysical 3D Induced Polarization survey to begin this week. This state-of-the-art geophysical survey will cover WPC, and Last Hurrah targets. CEO, Kit Marrs stated, "We are excited about the commencement of the upcoming drill season as we expand on our high grade Waterpump Creek mineralization with the aid of a new heavy duty drill rig designed to enhance drill production and core recovery. In 2022, we defined a 450-meter strike length of very high-grade silver-lead-zinc mineralization, and we anticipate extending the manto this year by potentially 2X or 3X. The Dias 3D IP survey could be a game changer for our program. We anticipate that it will provide high-definition drill targeting data."

07:38 EDT SPX Corporation completes acquisition of ASPEQ Heating Group - SPX Technologies completed the acquisition of ASPEQ Heating Group including certain tax attributes for $418 million in cash, subject to closing adjustments. ASPEQ, a provider of electrical heating solutions to customers in industrial and commercial markets, is now a part of SPX Technologies' HVAC Heating platform.

07:36 EDT SL Green signs 31 office leases covering 299,137 square feet in last 60 days - SL Green Realty has signed 31 office leases covering 299,137 square feet to date in the second quarter, increasing 2023 office leasing volume to 803,819 square feet, while maintaining an office leasing pipeline in excess of 1.0 million square feet.

07:33 EDT Ocugen announces Business Advisory Board - Ocugen announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's therapies around the world. Ocugen's Business Advisory Board members have been selected based on their extensive professional backgrounds and proven track record of creating partnerships among the public and private sector. Members include: Ambassador Joseph W. Westphal, PhD, Global Senior Fellow at the Joseph H. Lauder Institute of Management and International Studies at The Wharton School of The University of Pennsylvania. Pat Toomey, U.S. Senator who represented Pennsylvania from 2011 to 2023. Dennis Carey, PhD, Vice Chairman of Korn Ferry, where he recruits Board Directors, CEOs, and their direct reports.

07:28 EDT Tonix Pharmaceuticals presents data on TNX-601 ER, TNX-4300 - Tonix Pharmaceuticals Holding announced the presentation of data detailing the mechanism of action and pharmacokinetics of TNX-601 ER and TNX-4300 at the American Society of Clinical Psychopharmacology meeting in Miami, Fla. TNX-601 ER is being tested in a potentially pivotal Phase 2 trial for the treatment of major depressive disorder for which results of a preplanned interim analysis are expected in the fourth quarter of 2023. TNX-4300 is in preclinical development for mood disorders, Alzheimer's disease and Parkinson's disease. The active ingredient of both products is the (S)-isomer of tianeptine.1 The (S)-isomer of tianeptine activates PPAR-beta/delta, restores neuroplasticity in neuronal tissue culture and lacks micro-opioid liability. In contrast, the (R)-isomer of tianeptine lacks PPAR-beta/delta activity and is an agonist at the micro-opioid receptor. The poster presentation is available on Tonix's website: www.tonixpharma.com. Tonix recently announced that the plastogen anti-depressant tianeptine, a drug marketed outside the U.S. for more than 30 years, acts on nuclear PPAR-beta/delta and PPAR-gamma in neurons and glia to restore neuronal connectivity in depression.2 The understanding that tianeptine bypasses the synapse and acts on the nucleus to exert its effects on restoring neuroplasticity and neurogenesis has direct applicability in a number of neurodegenerative diseases in which neuronal connections are atrophying.2 The newly reported mechanism also provides clarity on why tianeptine is not associated with sexual dysfunction, weight gain or several other treatment-limiting toxicities, which are associated with the antidepressants currently marketed in the U.S. for long-term use. The findings reported at the meeting show how the pharmacokinetics of oral TNX-601 ER in humans differ from intraperitoneal tianeptine in mice. In humans, after an oral dose of TNX-601 ER the half-life of tianeptine in the blood is approximately 5-7 hours. In contrast, in mice after an i.p. dose of tianeptine the half-life of tianeptine in the blood has been reported to be less than approximately 30 minutes and the behavioral effects appear dominated by the longer-lasting MC5 metabolite, which maintains micro-opioid receptor activity. The data Tonix presented also show that the (R)-isomer of tianeptine is responsible for the decrease in immobility in the mouse forced swim test after i.p. administration, which is consistent with previous reports that the effect of tianeptine on the forced swim test is a micro-opioid receptor-dependent phenomenon.

07:26 EDT Bellerophon says Phase 3 REBUILD trial did not meet primary endpoint - Bellerophon Therapeutics announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse for the treatment of fibrotic Interstitial Lung Disease. The REBUILD clinical trial was designed as a randomized, double-blind, placebo-controlled Phase 3 study evaluating the safety and efficacy of INOpulse for the treatment of patients with fILD. A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or a placebo. The primary endpoint was the change in moderate to vigorous physical activity as measured by actigraphy after 16 weeks of chronic treatment. The trial did not meet its primary endpoint, with iNO45 performing worse than placebo by 5.49 minutes per day. The secondary endpoints demonstrated minimal difference between the two groups with none approaching statistical significance. Overall, INOpulse was well-tolerated with no safety concerns, consistent with what has been observed in the prior Phase 2 studies. Key REBUILD clinical trial secondary endpoints and safety outputs assessed over 16 weeks of blinded treatment included: Overall Activity showed 3.51 count/min benefit in favor of iNO45; 6 Minute Walk Distance showed 0.19 meter benefit in favor of iNO45; Patient reported outcomes were slightly in favor of placebo, while time to event assessments showed little difference and none were statistically significant; Subjects with treatment emergent adverse events was slightly in favor of placebo; Subjects with serious treatment emergent adverse events was balanced; Deaths were balanced.

07:23 EDT EyePoint completes enrollment in Phase 2 PAVIA trial of EYP-1901 - EyePoint Pharmaceuticals completed enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for moderate to severe non-proliferative diabetic retinopathy. PAVIA is a 12-month, randomized, controlled Phase 2 clinical trial of EYP-1901 in patients with moderate to severe NPDR. The trial enrolled 77 patients randomly assigned to one of two doses of EYP-1901, or to the control group receiving a sham injection. EYP-1901 is delivered with a single intravitreal injection in the physician's office. The primary efficacy endpoint of the trial is improvement of at least two diabetic retinopathy severity scale levels as of week 36 after the EYP-1901 injection. Secondary endpoints include reduction in vision-threatening complications, occurrence of diabetic macular edema and/or proliferative disease, retinal ischemia/nonperfusion and safety.

07:22 EDT NRx Pharmaceuticals, Lotus Pharmaceuticals, Alvogen collaborate for NRX-101 - Lotus Pharmaceuticals (LTUS), Alvogen and NRx Pharmaceuticals Inc. (NRXP) announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression for global markets. Under the terms of the agreement, relating to NRX-101 for the U.S. market, NRx is entitled to receive an initial payment of $10 million upon achieving both a successful read-out from the ongoing Phase 2b/3 clinical trial in S-TRB and completion of a Type B meeting with the U.S. Food and Drug Administration. NRx would receive an additional payment of $5 million upon receipt of FDA approval for NRX-101 as well as bonus milestone payments of increasing amounts up to $330 million based on reaching certain net sales targets. In addition to success-based payments, NRx is eligible to receive a royalty on net sales between 12% and 16% contingent on certain sales thresholds for the U.S. market and other success-based payments for markets outside of the U.S. Lotus will acquire worldwide rights for NRX-101 for treatment of S-TRBD and will be responsible for commercialization of NRX-101 in markets outside of the U.S. through their direct commercial presence in certain Asian markets or through Lotus's export division where the company currently markets an extensive portfolio of products through top-tier partners. Lotus will partner with Alvogen, a longstanding partner for Lotus in the U.S., to commercialize NRX-101 for treatment of S-TRBD in the U.S. market through Alvogen's Almatica label. Almatica is the CNS-focused division of Alvogen that currently markets six branded products. Alvogen and Lotus have committed to fund the next registrational study in suicidal treatment-resistant bipolar depression to support approval of NRX-101 contingent upon successful results of the ongoing Phase 2b/3 clinical trial and completion of a Type B meeting with the FDA. Lotus and Alvogen will have a right of first negotiation for new indications outside of the field of bipolar depression with suicidality for NRX-101 and/or potential new products containing D-cycloserine in combination with an antidepressant / antipsychotic.

07:19 EDT Oncolytics announces updated results from its BRACELET-1 trial - Oncolytics Biotech announced updated results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer, which include data featured in an oral presentation at the 2023 American Society of Clinical Oncology, ASCO, Annual Meeting, as well as additional new data and analyses. BRACELET-1 enrolled 48 patients, including 45 that were randomized and well-balanced across three cohorts evaluating: paclitaxel monotherapy; paclitaxel in combination with pelareorep; and paclitaxel plus pelareorep in combination with the anti-PD-L1 checkpoint inhibitor, avelumab. Updated data from BRACELET-1 showed a median progression-free survival of 9.5 months in the paclitaxel plus pelareorep cohort vs. 6.3 months in the paclitaxel monotherapy cohort for a hazard ratio of 0.29 as of a March 3, 2023 cut-off date. Confirmed overall response rate, ORR, in these cohorts was 37.5% and 13.3%, respectively. As previously reported, ORR at week-16 in the pelareorep plus paclitaxel and paclitaxel monotherapy cohorts was 31.3% and 20%, respectively. Overall survival data from the trial continue to mature. Key biomarker and safety findings from BRACELET-1 include: Association between T cell expansion and efficacy measures: A statistically significant increase in T cell fraction, a measure of T cell expansion, was observed in cohort 2 but not cohort 3. Generally favorable and manageable safety profile: Pelareorep displayed a manageable safety profile consistent with what has been observed in prior clinical trials that have collectively treated over 1,100 patients

07:18 EDT Foghorn Therapeutics sees cash runway into 2H25 - "With a focus on patient safety, we have worked with the FDA to resolve the clinical hold on FHD-286 in AML and MDS," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "Clinical data suggest FHD-286 is a potent, broad-based differentiation therapeutic, and we believe it has significant combination potential as a treatment in AML. We anticipate commencing a Phase 1 combination study focusing on first-line relapsed and/or refractory AML patients in the third quarter of 2023."

07:17 EDT Biolase is reducing its U.S. workforce by 20% to improve operating efficiency - BIOLASE is taking the necessary steps to optimize operations to capitalize on the rising business momentum for its market-leading dental lasers. The Company remains committed to advancing the field of dentistry through cutting-edge laser solutions while achieving profitability. To ensure its steadfast pursuit of this objective is achieved, the Company is reducing its US workforce by approximately 20%, resulting in a projected annualized cost savings of approximately $4 million. "We believe today's action increases BIOLASE'S operational effectiveness, while the cost savings should allow us to allocate additional resources to revenue-generating initiatives and position us for sustained long-term success in the dental technology industry," commented John Beaver, President and Chief Executive Officer at BIOLASE. "Our strategy of transforming dentistry with innovative laser technologies has not wavered because of this development, and we expect this will have zero impact on our ability to drive sales growth and maintain our market-leading position. These optimization efforts allow us to focus on our growth and profitability targets without compromising our commitment to customer satisfaction and market expansion. We have also accelerated our in-house production of certain key components that will significantly improve our gross margin in the future. These initiatives, along with other cost optimization strategies being implemented should help us meet our goal of being adjusted EBITDA positive this year."

07:16 EDT Veeva announces over 450 companies using Veeva Vault eTMF - More than 450 biopharma companies-including 18 of the top 20 pharmas and 4 of the top 6 CROs-use Veeva Vault eTMF to automate trial processes and improve information exchange across stakeholders. "We're excited to continue partnering with customers to advance TMF for more efficient, compliant clinical trials," said Jason Methia, vice president, Veeva Vault Clinical Operations strategy. "By delivering Veeva Vault eTMF innovations, we're tackling challenges that can significantly streamline study processes and move the industry forward."

07:15 EDT Lucid Diagnostics launches first EsoGuard mobile test unit - Lucid Diagnostics (LUCD), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed (PAVM), announced the launch of its first EsoGuard #CheckYourFoodTube Mobile Test Unit serving patients and practices in the Greater Central Florida area. Florida Digestive Health Specialists, Florida's largest gastroenterology network, will co-host the inaugural precancer detection event at the Gastroenterology Associates of Sarasota offices in Sarasota, Florida under the direction of Dr. Scott Corbett, Chief of Gastroenterology at Sarasota Memorial Hospital. "This expansion into mobile testing is yet another example of our relentless commitment to bringing EsoGuard testing to at-risk patients in order to detect precancer and prevent devastating esophageal cancer," said Lishan Aklog, M.D., Lucid's Chairman & Chief Executive Officer. "We believe that mobile testing will strongly complement our satellite Lucid Test Center and high-volume precancer detection event programs."

07:14 EDT Numinus' CCR is top clinical research site for MindMed's Phase 2b study - Numinus Wellness (NUMIF) announces Cedar Clinical Research, CCR, is a top research site for MindMed's (MNMD) Phase 2b study evaluating MM-120 for General Anxiety Disorder. CCR's research clinic in Draper, Utah, is the top enrolling site for the research study - having enrolled and dosed 19 clinical trial participants for the study to date. CCR also recently began enrolling volunteers for this trial at a second research clinic - in Murray, Utah. "We're excited to support MindMed in their clinical trial work, by evaluating new important treatments and protocols to address mental health disorders," said Paul Thielking, Chief Science Officer, Numinus, and Principal Investigator at CCR Murray. "The fact that our Draper research clinic is the top enrolling site for the study underscores the quality of our clinical research capabilities and recruiting efforts."

07:12 EDT Compugen announces preliminary results of COM701 with nivolumab, BMS-986207 - Compugen announced data to be presented at the American Society of Clinical Oncology, ASCO, Annual Meeting, showing that Compugen's COM701 in triple combination with nivolumab and BMS-986207 demonstrated preliminary signal of durable anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer with a favorable safety profile. Preliminary translational data showed an association between greater peripheral immune activation and clinical benefit. Henry Adewoye, MD., Chief Medical Officer of Compugen, added, "I am delighted to see the preliminary data we have reported, including a confirmed partial response in a patient with endometrial carcinosarcoma, a rare hard-to-treat histologic type of endometrial cancer that is not typically responsive to standard of care therapies. The translational findings in patients with clinical benefit are also in line with the mechanistic rationale of the combination. Although the number of patients enrolled is small, these data and the clinical signal reported support our hypothesis of blocking the DNAM-1 axis with anti-PVRIG, TIGIT and PD-1 antibodies."

07:10 EDT Harsco changes name to Enviri Corporation - Harsco Corporation will change its name to Enviri Corporation effective immediately. The Company will begin trading under the NYSE ticker "NVRI" on June 19, 2023. The new name and brand identity reflect the Company's transformation over the past four years into a single-thesis environmental solutions company that provides services to manage, recycle and beneficially reuse waste and byproduct materials across many industries."As we considered where we are today, how our business has evolved and our commitment to the environment, it is important to have a name and brand identity that align with this image," said Nick Grasberger, CEO We are energized as we enter into this new era and look forward to continuing to operate with the same commitment to excellence that has been part of the Company's legacy for more than 170 years, while providing value for our investors, customers, partners and the communities in which we operate." While the Company has changed its legal name to Enviri, Harsco Environmental, Clean Earth and Harsco Rail, will continue to operate under their existing names as divisions of Enviri.

07:09 EDT Perimeter Medical Imaging AI announces CEO Sobotta resigned, Mendes to succeed - Perimeter Medical Imaging AI announced that Jeremy Sobotta has resigned as Chief Executive Officer of the Company, effective June 15, 2023, for personal reasons. Perimeter has also announced that the Board of Directors has appointed Adrian Mendes as Chief Executive Officer, effective immediately. Sobotta will work closely with Mendes over the coming weeks to ensure a smooth transition of responsibilities. Most recently, Mendes was the Chief Operating Officer at Groq, an AI hardware company. In addition, Perimeter announced that Josh Vose, MD, MBA has been appointed to its Board of Directors, effective immediately. Most recently, Dr. Vose served as CEO and Board Director at SIA Health.

07:07 EDT Chemomab Therapeutics announces leadership changes, Mor appointed CEO - Chemomab Therapeutics announced changes to its executive leadership team and provided a corporate update. Adi Mor, PhD, co-Founder and former Chief Executive Officer, CEO, of Chemomab, and current Director and Chief Scientific Officer, has been reappointed to the role of CEO, replacing Dale Pfost, PhD. Sigal Fattal, former Chief Financial Officer, CFO, and current Vice President, Finance, has been reappointed to the role of CFO, replacing Donald Marvin. Current Director Nissim Darvish, MD, PhD, has been appointed Chairman of the Board, replacing Dr. Pfost. All the appointments were effective June 1, 2023.

07:07 EDT Circor to be acquired by KKR in $1.6B all cash transaction - Circor (CIR) announced that it has entered into a definitive agreement to be acquired by investment funds managed by KKR (KKR) in an all cash transaction valued at approximately $1.6B, including the assumption of debt. Under the terms of the agreement, KKR will acquire all outstanding shares of Circor common stock for $49 per share in cash, representing a 55% premium to the company's closing stock price on June 2, 2023. KKR is making its investment in Circor through its North America Fund XIII. The investment builds on KKR's recent experience investing in flow control technologies and aerospace and defense industry suppliers globally. Following the close of the transaction, KKR will support Circor in expanding its equity ownership program to allow all employees to have the opportunity to participate in the benefits of ownership of the company. This strategy is based on the belief that employee engagement is a key driver in building stronger companies. Since 2011, KKR portfolio companies have awarded billions of dollars of total equity value to over 50,000 non-management employees across nearly 30 companies.

07:01 EDT Palantir awarded $463M contract from USSOCOM - Palantir announced it was awarded a contract from the US Special Operations Command, or USSOCOM, to deliver technology solutions to support enterprise capabilities. The multi-year contract is worth up to $463M. Palantir provides best in class software capabilities for America's warfighters, including the men and women of USSOCOM, and this contract award will help ensure their continued competitive advantage in this next phase of competition. Palantir helps USSOCOM to parse the petabytes of data emanating from today's environments and enables decision-making. Palantir is driving rapid innovations across its Defense Portfolio. These include advancements in Large Language Models, or LLMs, to reduce cognitive load on warfighters and commanders; as well as advancements in edge processing and edge AI to maximize the warfighter's ability to integrate and utilize real-time information. This contract is the result of the trust built on more than a decade of work between our communities, and is a reaffirmation of Palantir's commitment to always provide the most capable software for the U.S. warfighters who need it most.

06:58 EDT International Game signs 10-year licensing pact with Sony Pictures Television - International Game announced that it has signed a ten-year licensing agreement with Sony Pictures Television that grants the company exclusive rights to the legendary Wheel of Fortune brand across gaming, lottery, iGaming and iLottery and non-exclusive rights to distribute Wheel of Fortune content for free-to-play social casinos. The contract will run January 1, 2025 to December 31, 2034.

06:55 EDT Golden Minerals provides update on Unifin dispure - The company said, "As previously disclosed, the Company is party to a lawsuit in Mexico brought by Unifin Financiera, S.A.B. de C.V. Unifin is alleging that a representative of the Company's subsidiary, Minera William, S.A. de C.V. signed certain documents in July 2011 purporting to bind Minera William as a guarantor of payment obligations owed by a third party to Unifin in connection with that third party's acquisition of certain drilling equipment. At the time the documentation was allegedly signed, Minera William was a subsidiary of ECU Silver Mining prior to the Company's acquisition of ECU in September 2011. A preliminary hearing on the lawsuit was held on June 2, 2023 and the trial hearing has been scheduled for June 30, 2023. Unifin is seeking recovery for as much as US$12.5 million. Because the Velardena mine and processing plants are held by Minera William, any adverse outcome of the action may have a material impact on our ability to restart production at Velardena."

06:53 EDT Golden Minerals plans to restart silver, gold mining operations at Velardena - Golden Minerals Company plans to restart silver-gold mining operations at its Velardena Properties located in Durango State, Mexico, subject to the receipt of sufficient capital. Warren Rehn, CEO, stated, "I am very pleased to announce that Golden Minerals' board of directors has approved plans to restart mining operations at Velardena. The decision to begin operations again at Velardena was primarily based on vastly improved sales terms now available to us for the gold-rich pyrite concentrate that is produced from flotation processing of Velardena mineralized material, which permit us to restart operations without the significant expense of the previously planned bio-oxidation facility. Since the start of 2023, we successfully processed 3,000 tons of material mined in our test mining activities in 2022 and we sold approximately 600 tons of these concentrates under the improved terms with net receipts of approximately $1.5 million or about $500 per ton of mined material. These recent sales augur well for the potential success of our restart plans. We anticipate that we can start mining operations with minimal initial capital of approximately $0.5 million. Our internally developed mine plan projects the production of approximately 0.4 million silver equivalent ounces1 during 2023, with the potential to ramp up to approximately 1.6 million silver equivalent ounces per year thereafter. We have contracted for completion of an independent technical report, which we expect will support our internal projections. We intend to begin preparations to start mining immediately." Our internal mine plan calls for underground resue mining, starting with four active stopes initially with processing at Velardena's Plant I flotation facility at an initial throughput rate of approximately 80 tonnes per day. As underground development progresses, the number of stopes is anticipated to steadily increase over a period of months until 15 to 18 stopes are ultimately in continuous production. The mill is expected to reach a steady-state processing rate of approximately 325 tpd by the end of the year. All required permits are already in place, and because Plant I has recently been in use and processing previously mined Velardena sulfide material, after startup as development costs continue to exceed net revenue, the maximum cash outflows of about $2.3 million, inclusive of the initial $0.5 million, are predicted to be paid back within the first nine months of operations. The Company, through engagement with an independent engineering firm, intends in the third quarter of 2023 to update the March 2022 Technical Report Summary for Velardena that was previously completed in accordance with SEC SK-1300 guidelines. That report is available here, for reference: Velardena Technical Report Summary, Mar. 2022. It summarizes the underlying model from which the Company's current internally-developed forecasts have been developed. Current Company-developed forecasts for mining a portion of the published resource over an approximate seven-year life of mine estimate processing 700,000 - 800,000 tonnes of material at Plant I, with LOM payable gold production of 60,000 - 70,000 ounces and LOM payable silver production of 5.5 million - 6.5 million ounces. Operating costs are estimated at $225 - $275 per tonne.

06:51 EDT Wesdome Gold Mines appoints Anthea Bath as president, CEO - Wesdome Gold Mines announced the appointment of Anthea Bath as President and CEO effective July 1, 2023. Warwick Morley-Jepson, Board Chair and Interim CEO, will continue his role as Interim CEO until Ms. Bath commences employment with the Company, and thereafter will resume his role as Independent Board Chair. Most recently, Anthea was the COO at Ero Copper.

06:47 EDT Synlogic initiates Synpheny-3 Global Phase 3 study of SYNB1934 - Synlogic announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria. Synpheny-3 is a randomized, placebo-controlled, global, multi-center, pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of SYNB1934 as a treatment for PKU. The final trial design incorporates feedback from global regulatory agencies including the U.S. Food and Drug Administration. The global study will enroll approximately 150 patients with plasma phenylalanine levels at baseline of greater than360 muM. Synpheny-3 will include patients ages 18 years and older; an initial subset of data from patients in Part 1 will be used to assess the opportunity to lower the age of enrollment to 12 years of age. Study participants may follow their usual diet while participating in the trial. Synpheny-3 is expected to be conducted at approximately 30 clinical sites across the United States, Canada, Germany, Denmark, Israel, Turkey and Georgia. The study has been designed for patient convenience, and offers opportunities to participate in person, or in a virtual or hybrid format. The study consists of three parts: Part 1 is a run-in period, enabling individualized titration across three potential dose levels, with patients spending a minimum of three weeks at each dose. Part 2 of the trial is a four-week, placebo-controlled, randomized withdrawal that will be used to assess the primary endpoint: change in levels of plasma Phe, with a primary analysis conducted among responders from Part 1. The definition for responders is a reduction in plasma Phe from baseline of greater than20%. Part 3 is an open-label extension that may extend for up to three years.

06:42 EDT SpringsWorks announces PDUFA date extension for nirogacestat NDA - SpringWorks Therapeutics announced that the U.S. Food and Drug Administration has updated the Prescription Drug User Fee Act action date for the New Drug Application for nirogacestat for the treatment of adults with desmoid tumors. The previously disclosed August 27, 2023 PDUFA date has been extended by the standard extension period of three months. The FDA notified SpringWorks on June 2, 2023 that it required more time to review additional analyses of previously submitted data that had been provided by SpringWorks in response to the FDA's information requests. The submission of this additional information was determined by the FDA to constitute a Major Amendment to the NDA, thereby resulting in an extension of the PDUFA action date. No additional data or studies have been requested by the FDA at this time. The NDA for nirogacestat was granted Priority Review upon its acceptance by the FDA in February 2023 and is being reviewed under the FDA's Real-Time Oncology Review program. It is based on positive data from the Phase 3 DeFi trial which were published in the March 9, 2023 edition of the New England Journal of Medicine.1 The FDA previously granted Breakthrough Therapy, Fast Track and Orphan Drug designations for nirogacestat. In addition, SpringWorks expects to file a Marketing Authorization Application for nirogacestat with the European Medicines Agency in 2024.

06:40 EDT New Found Gold announces results from diamond drill hole at Iceberg - New Found Gold is pleased to announce the results from one diamond drill hole that was completed as part of a follow-up drill program at the new Iceberg discovery, a high-grade zone located 300m northeast of Keats Main along the highly prospective Appleton Fault Zone. New Found's 100%-owned Queensway project comprises a 1,662 km2 area, accessible via the Trans-Canada Highway, 15km west of Gander, Newfoundland and Labrador. NFGC-23-1210 intersected 105 g/t Au over 27.05m just 35m from surface at Iceberg. High-grade mineralization is well distributed throughout the composite with nine individual sample intervals registering over 100 g/t Au. The hole is located 32m along strike of previously reported 49.7 g/t Au over 29.85m in NFGC-23-1120 and 30m down-dip of previously reported 15.3 g/t Au over 10.75m in NFGC-22-1084. Iceberg is currently drill-defined over a strike length of 550m and represents the fault-displaced eastern extent of the Keats-Baseline Fault Zone, the same fault that hosts Keats Main. Presently, the Keats Main-Iceberg-Iceberg East mineralized corridor has a combined strike length of 1.8km. Iceberg-Iceberg East remains open in all directions and drilling is ongoing to expand along strike and to depth with several intervals currently pending assay results.

06:37 EDT Marriott to launch affordable midscale extended stay brand - Marriott announced its plans to further expand in the affordable midscale lodging segment, following its recent entry into the segment with City Express by Marriott in Latin America. Consistent with the company's approach to meeting the needs of guests with regionally relevant lodging products for every stay purpose, Marriott is announcing its plans to launch a new brand, which has not yet been named, but is currently being referred to as Project MidX Studios. The affordable midscale extended stay brand is intended to deliver reasonably priced modern comfort for guests seeking longer stay accommodations in the U.S. & Canada. Project MidX Studios, expected to be Marriott's most affordable cost-per-room product in the U.S. & Canada, is designed to enable accelerated speed-to-market with a low cost to build. The prototype model targets a build cost of $13M to $14M, requiring approximately 54,000 square feet of total building area for 124 studios. The brand is also expected to have a light operational cost model for owners and franchisees.

06:28 EDT FCM MM Holdings condemns ISS report issued on Mind Medicine - FCM MM Holdings, representing approximately 3.5% of the outstanding common shares of Mind Medicine, condemned the report issued by proxy advisor Institutional Shareholder Services. The firm said, "ISS' dismissal of the 47% drop of MindMed's shares following the September 2022 financing as merely in line with 'sectoral trends', notwithstanding that MindMed's peers began selling off two weeks later, is illustrative of its lack of critical analysis. To accept ISS' recommendation to stay the course would be to ignore the Board's failed clinical strategy that continues to destroy shareholder value. We believe MindMed's Board must be held accountable for their inability to act as independent fiduciaries for shareholders, punishing shareholders with a massively dilutive financing, and allowing management free rein to spend scarce shareholder capital. ISS not only flip-flops on its 2022 recommendation to remove Carol Vallone as Chair of the Board, but then takes Ms. Vallone's word, as chair of compensation committee, for why she is deserving of "outlier" compensation. ISS Report parroted MindMed's previously refuted statement regarding MindMed's G&A costs relative to Compass Pathways. ISS Report turns a blind eye to report that MindMed took actions that we believe jeopardized patient safety by giving a drug at 35 times the dose the FDA had deemed safe...In arriving at its flawed and superficial report, ISS bafflingly dismissed serious deficiencies noted in their report about the Board's oversight of the Company, including: MindMed's fundamentally flawed clinical development strategy that has been plagued by delays and failure. MindMed management's lack of experience and expertise, with executives and advisors Barrow, Karlin, and Liechti never having brought a drug to market, that has led to fundamental errors in the Company's approach to clinical development. Ignoring FCM's unrefuted analysis of real-world CNS drug outcomes, while accepting Greenleaf Health, Inc.'s paid report as sufficient validation for the Company's clinical path and failing to note that the report did not deny the ability of MindMed to execute FCM's superior plan. The Company's September 2022 financing was punitive and massively dilutive to existing shareholders - that by ISS' acknowledgement took the shares down over 47% the day after the financing - which ISS characterized implausibly as in line with "sectoral trends." Analyst projections showing that MindMed is expected to run out of money in 2024 and that shareholders should expect 50-100% dilution to compensate. The Company's bloated G&A expenses and headcount that are consuming scarce shareholder capital that should be devoted to clinical development. A massive pay for performance disconnect that continues to reward management for their failed leadership. The ISS report failed to address critical issues that FCM raised including: MindMed's MM-110 program that dosed patients at 35 times higher than what had been deemed safe by the FDA, then obscured the facts about the program in successive investor disclosures, and ultimately wasted $19 million. The Board's lack of alignment with shareholders, owning just 0.22%1 of the outstanding MindMed shares vs. FCM's 3.5% beneficial ownership, which our principals have committed to hold until June 15, 2025. The numerous unfulfilled promises that MindMed has made include purported partnerships in digital medicine and Phase II trials. FCM's credible plan and nominees who can put MindMed's drug development plan back on track."

06:23 EDT Fusion Fuel appoints Frederico Figueira de Chaves as CEO - Frederico Figueira de Chaves, previously Co-Head and CFO, has been appointed CEO of the Company. The company also announced that Gavin Jones has been appointed interim CFO in addition to his existing responsibilities as Chief Accounting Officer. Andre Antunes, previously Chief Production Officer, has been promoted to COO. In addition, Jaime Silva has been appointed Head of Innovation in addition to his current role of Chief Technology Officer, a title change which more accurately reflects the responsibilities of his role. Lastly, Zachary Steele and Jason Baran have decided to leave Fusion Fuel and will be stepping down from their roles of Co-Head and CCO, respectively, as well as Co-Presidents of the Americas, to pursue other opportunities in the hydrogen and clean fuels sector.

06:04 EDT Anaergia to build sludge co-digestion facility at Monterey One Water - Anaergia will provide technologies that will enable Monterey One Water, the wastewater utility of northern Monterey County, California, to make renewable energy from food waste as well as wastewater. The project will significantly expand anaerobic digestion capacity at Monterey One Water's Regional Treatment Plant in Marina, California, and provide organic waste receiving and pre-processing equipment. This will allow the utility to receive and co-digest food waste in existing digesters currently used to process wastewater biosolids. When anaerobically digested, the waste produces renewable biogas, which is then used to generate electricity and heat at the Monterey One plant. The project will increase biogas production from the plant's four digesters by more than 150%, which will be used to make up to 1.6 MW of renewable electricity via on-site combined heat and power engines. The increased energy production will provide more than 100% of the plant's power needs, significantly reducing operating costs, supporting revenue generation, and increasing resiliency and reliability. This significant expansion in onsite energy generation is a major asset to the development of a joint microgrid that will be shared by Monterey One neighbor and regional solid waste agency, ReGen. CalRecycle, California' Department of Resources Recycling and Recovery, will provide $4,218,900 in grant funds, minimizing impact on the utility's ratepayers by offsetting most of the project's cost. Work on the project is expected to begin in Q2 2023 and be completed by Q3 2024.

05:53 EDT Diageo board appoints Debra Crew interim CEO - Diageo said in a statement that "Sir Ivan Menezes is currently in hospital receiving treatment for medical conditions including a stomach ulcer. Over the weekend, we learned that Ivan's recovery suffered a significant setback due to complications, which followed emergency surgery on the ulcer. As a result of these developments, the Board of Directors has appointed Debra Crew Interim CEO with immediate effect, ahead of her appointment as CEO and joining the Board as an executive director on 1 July 2023. As previously announced, Ivan will retire from the Board on 30 June 2023." Reference Link

05:23 EDT Cyxtera Technologies initiates Chapter 11 process - Cyxtera announced that, pursuant to the previously disclosed restructuring support agreement, or RSA, it reached with certain of its lenders holding over two-thirds of its outstanding term loan, the company and certain of its subsidiaries have initiated a pre-arranged court-supervised process under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of New Jersey. Cyxtera expects to use the Chapter 11 process to strengthen the company's financial position, meaningfully deleverage its balance sheet and facilitate the business's long-term success. Cyxtera is continuing to operate its global platform of interconnected data centers normally and without interruption. Customers also continue to have access to their Cyxtera data center sites and equipment as usual. Cyxtera has received a commitment for $200M in debtor-in-possession financing from certain of the term lenders, which is convertible into an exit facility upon the company's emergence from the court-supervised process. This new financing is expected to provide sufficient liquidity to support Cyxtera during this process and beyond. As Cyxtera moves through the court-supervised process, it is continuing to pursue a potential sale of the business or a significant investment from a new investor. The company has filed a number of customary motions with the court seeking authorization to support its operations, including the payment of employee wages, salaries and benefits without interruption. The company expects to receive court approval for these requests shortly. The company intends to pay vendors and suppliers in full for goods and services provided on or after the filing date. Cyxtera is continuing to evaluate its data center footprint, consistent with its commitment to optimizing operations. The company's subsidiaries in Germany, Singapore and the United Kingdom are not included in the court-supervised process.

05:13 EDT Expro announces $30M contract with TotalEnergies Uganda for Tilenga project - Expro (XPRO) has announced a five-year Well Intervention and Integrity contract with TotalEnergies (TTE) Uganda for the multi-well Tilenga project. The company said, "A key component in Expro securing a contract worth over $30 million for slickline services was its ability to provide an innovative environmental solution in support of the client's carbon reduction objectives, as well as Expro's commitment to national recruitment in line with a local development plan, working in collaboration with TotalEnergies and the Petroleum Authority of Uganda (PAU). Expro's solution placed significant focus on the location's sensitivity near a national park. The company is providing environmentally sympathetic lower carbon operations solutions compared to current market alternatives. Expro has also invested in a new operational facility in-country, supported by investment in people and training to help exceed local expectations. Work begins in Q2 2023, with Expro initially supporting drilling activity followed by production optimization, integrity and well workover support. Expro has designed four well intervention units to deliver a single operational solution for slickline and braided line in a cased hole environment across the life of the well. The solution is designed to reduce equipment footprint and equivalent CO emissions, while delivering improved efficiency. The Tilenga project covers six fields, with over 400 wells planned across multiple pads. Drilling will start this year and continue for five years."

05:07 EDT Papa John's acquires portfolio of 91 restaurants from DFSI, terms undisclosed - Papa John's announced the acquisition of restaurants previously operated by the M25 division of Drake Food Service International, or DFSI, in the United Kingdom. The transition of restaurants will establish a portfolio of company-owned restaurants in the market. Financial terms of the transaction were not disclosed. The new corporate-owned restaurant portfolio will consist of 91 locations across London and other parts of the U.K. The company sees opportunities to implement operating model enhancements including revenue management capabilities, product and technological innovation and operational efficiencies, to improve sales and restaurant-level profitability. As part of the transition, approximately 1,000 employees working for DFSI M25 will become team members of the company. Minimal, if any, disruption to customers is expected during the transition time. DFSI will continue to hold its master franchise rights for Papa Johns in Spain, Portugal, Chile and Central America.